

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE ⁺	Germany	MC	Monaco	US	United States of America
DK	Denmark				

⁺ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

DEVICE FOR DELIVERING AN AEROSOLTechnical Field

This invention relates to devices for
5 delivering aerosols. In another aspect this invention
relates to sealing members. In yet another aspect this
invention relates to sealing members for use in devices
for delivering aerosols. This invention also relates
to thermoplastic polymer blends.

10

Description of the Related Art

The continuing use of aerosol formulations
comprising conventional chlorofluorocarbon propellants
is being debated due to the suspected role of such
15 propellants in atmospheric depletion of ozone.
Accordingly, alternative propellants such as HFC-134a
(1,1,1,2-tetrafluoroethane) and HFC-227 (1,1,1,2,3,3,3-
heptafluoropropane) are being developed to replace
those conventional propellants thought to contribute to
20 atmospheric ozone depletion.

Containers for aerosol formulations
commonly include a rubber valve seal intended to allow
reciprocal movement of the valve stem while preventing
leakage of propellant from the container. These rubber
25 valve seals are commonly made of thermoset rubbers such
as butyl rubber, butadiene-acrylonitrile rubbers,
("Buna") and neoprene (polychloroisoprene), which are
compounded with vulcanizing agents prior to being
fashioned into valve seals.

30

Summary of the Invention

It has been found that some conventional
devices for delivering aerosols suffer impaired
performance when used in connection with HFC-134a
35 and/or HFC-227. Accordingly, this invention provides a
device for delivering an aerosol, comprising: a valve
stem, a diaphragm having walls defining a diaphragm
aperture, and a casing member having walls defining a

- 2 -

casing aperture, wherein the valve stem passes through the diaphragm aperture and the casing aperture and is in slidable sealing engagement with the diaphragm aperture, and wherein the diaphragm is in sealing engagement with the casing member, the diaphragm material comprising: a thermoplastic elastomer comprising a copolymer of about 80 to about 95 mole percent ethylene and a total of about 5 to about 20 mole percent of one or more comonomers selected from the group consisting of 1-butene, 1-hexene, or 1-octene (i.e., the total amount of comonomer in the copolymer is about 5 mole percent to about 20 mole percent).

This invention also provides a metered-dose device for delivering an aerosol that comprises, in addition to the above-discussed valve stem, diaphragm, and casing member, a tank seal having walls defining a tank seal aperture, and a metering tank of a predetermined volume and having an inlet end, an inlet aperture, and an outlet end, wherein the outlet end is in sealing engagement with the diaphragm, the valve stem passes through the inlet aperture and the tank seal aperture and is in slidable engagement with the tank seal aperture, and the tank seal is in sealing engagement with the inlet end of the metering tank, and wherein the valve stem is movable between an extended closed position, in which the inlet end of the metering tank is open and the outlet end is closed, and a compressed open position in which the inlet end of the metering tank is substantially sealed and the outlet end is open to the ambient atmosphere.

In a preferred embodiment the casing member defines a formulation chamber, and in a further preferred embodiment the formulation chamber contains an aerosol formulation comprising a propellant, said propellant comprising 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, or a mixture thereof.

In another aspect, this invention provides an elastomeric sealing member, e.g., for maintaining a

desired atmosphere in a sealed chamber or for minimizing and/or preventing escape of propellants, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane, from a sealed chamber. Such

5 sealing members can be used as appropriate in connection with static seals or dynamic seals, with pressurized or unpressurized systems, and with liquid or dry systems. The sealing member comprises a thermoplastic elastomer comprising a copolymer of about

10 80 to about 95 mole percent ethylene and a total of about 5 to about 20 mole percent of one or more comonomers selected from the group consisting of 1-butene, 1-hexene, and 1-octene. In a preferred embodiment the sealing member is used in a dynamic seal

15 in a pressurized system in order to prevent escape of formulation components, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane, from a device for delivering an aerosol.

20 This invention also provides thermoplastic polymer blends comprising at least two thermoplastic copolymers, each comprising a copolymer of about 80 to about 95 mole percent ethylene and a total of about 5 to about 20 mole percent of one or more comonomers

25 selected from the group consisting of 1-butene, 1-hexene, and 1-octene.

Devices, sealing members, and thermoplastic polymer blends of this invention find use in connection with aerosol formulations involving HFC-134a or HFC-227

30 as a propellant as well as with formulations containing other propellants such as chlorofluorocarbon propellants. Conventional devices involving thermoset diaphragms of neoprene (polychloroprene), butyl rubber, or butadiene-acrylonitrile "buna" copolymers allow

35 excessive leakage of HFC-134a and HFC-227 from some formulations over time. Particularly in low volume formulations such as pharmaceutical formulations for use in inhalation therapy, this leakage can cause a

- 4 -

substantial increase in concentration of the active ingredient in the formulation, resulting in delivery of an improper dose. Furthermore, with some formulations the valve stem tends to stick, pause, or drag during
5 the actuation cycle when neoprene or butadiene-acrylonitrile "buna" diaphragms are used. Leakage and smoothness of operation are improved in the devices of the invention compared to like devices involving the conventional diaphragm materials. Hence
10 this invention is particularly desirable for use with aerosol formulations wherein the propellant comprises HFC-134a, HFC-227, or a mixture thereof. Moreover, the thermoplastic elastomers used in the sealing members of the invention, including the thermoplastic polymer
15 blends of the invention, are not compounded with vulcanizing agents and therefore they are free of complications that might arise from contamination by leaching of such vulcanizing agents.

20 Brief Description of the Drawings

The drawing is represented by FIGS. 1 and 2. FIG. 1 is a partial cross-sectional view of one embodiment of a device of the invention, wherein the valve stem is in the extended closed position.

25 FIG. 2 is a partial cross-sectional view of the embodiment illustrated in FIG. 1, wherein the valve stem is in the compressed open position.

Detailed Description of the Invention

30 Unless otherwise indicated the copolymers described herein are random copolymers, i.e., the respective monomer units are substantially randomly distributed in the copolymer.

In order to minimize and/or prevent leakage
35 of refrigerants, propellants, or other formulation components, especially propellants such as 1,1,1,2-tetrafluoroethane and 1,1,1,2,3,3,3-heptafluoropropane, from a sealed chamber, this

invention provides thermoplastic elastomeric sealing members comprising a copolymer of about 80 to about 95 mole percent ethylene and a total of about 5 to about 20 mole percent of one or more comonomers selected from the group consisting of 1-butene, 1-hexene, and 1-octene. The thermoplastic elastomer can also contain minor amounts of conventional polymer additives such as processing aids, colorants, lubricants, and talc.

Suitable thermoplastic elastomers can be prepared using methods known to those skilled in the art. A preferred thermoplastic elastomer is FLEXOMERTM DFDA 1137 NT7 polyolefin (commercially available from Union Carbide), a thermoplastic elastomer comprising a copolymer of about 91 mole percent ethylene and about 9 mole percent 1-butene. This copolymer is said to have a density of 0.905 g/cm³ (ASTM D-1505) and a melt index of 1.0 g/10 min (ASTM D-1238). FLEXOMERTM DFDA 1138 NT polyolefin (commercially available from Union Carbide), a thermoplastic elastomer comprising a copolymer of about 91 mole percent ethylene and about 9 mole percent 1-butene and having a density of 0.900 g/cm³ (ASTM D-1505) and a melt index of 0.4 g/10 min (ASTM D-1238) is also suitable. A further suitable thermoplastic elastomer comprises a copolymer of about 88 mole percent ethylene and about 12 mole percent 1-butene. An example of such a thermoplastic elastomer is FLEXOMERTM DEFD 8923 NT polyolefin (obtained on an experimental basis from Union Carbide). This elastomer is said to have a density of 0.890 g/cm³ (ASTM D-1505), and a melt index of 1.0 g/10 min (ASTM D-1238).

Other exemplary suitable thermoplastic elastomers include:

FLEXOMERTM GERS 1085 NT polyolefin (Union Carbide), comprising a copolymer of about 80 mole percent ethylene and about 20 mole percent 1-butene, having a density of 0.884 g/cm³ (ASTM D-1505) and a melt index of about 0.8 g/10 min (ASTM D 1238);

- 6 -

FLEXOMER™ DFDA 1163 NT7 polyolefin (Union Carbide), comprising a copolymer of about 95 mole percent ethylene, about 1 mole percent 1-butene, and about 4 mole percent 1-hexene, having a density of
5 0.910 g/cm³ (ASTM D 1238) and a melt index of about 0.5 g/10 min (ASTM D 1238); FLEXOMER™ DFDA 1164 NT7 polyolefin (Union Carbide), comprising a copolymer of about 94 mole percent ethylene, about 1 mole percent 1-butene, and about 5 mole percent 1-hexene, having a
10 density of about 0.910 g/cm³ (ASTM D 1505) and a melt index of about 1.0 g/10 min (ASTM D 1238).

FLEXOMER™ 1491 NT7 polyolefin (Union Carbide), comprising a copolymer of about 90 mole percent ethylene and about 10 mole percent 1-butene,
15 having a density of 0.900 g/cm³ (ASTM D 1505) and a melt index of about 1.0 g/10 min (ASTM D 1238);

FLEXOMER™ 9020 NT7 polyolefin (Union Carbide), comprising a copolymer of about 92 mole percent ethylene and about 8 mole percent 1-butene,
20 having a density of 0.905 g/cm³ (ASTM D 1505) and a melt index of about 0.85 g/10 min (ASTM D 1238);

FLEXOMER™ 9042 NT polyolefin (Union Carbide), comprising a copolymer of about 80 mole percent ethylene and about 20 mole percent 1-butene,
25 having a density of 0.900 g/cm³ (ASTM D 1505) and a melt index of about 5.0 g/10 min (ASTM D 1238).

ATTANE™ 4602 polyolefin (Dow), comprising a copolymer of about 90 mole percent ethylene and about 10 mole percent 1-octene, having a density of 0.912
30 g/cm³ (ASTM D 792) and a melt index of about 3.3 g/10 min (ASTM D 1238);

ATTANE™ 4701 polyolefin (Dow), comprising a copolymer of about 92 mole percent ethylene and about 8 mole percent 1-octene, having a density of 0.912 g/cm³
35 (ASTM D 792) and a melt index of about 1.0 g/10 min (ASTM D 1238).

- 7 -

Blends of two or more of the above-described thermoplastic elastomers in any proportion are also suitable. Preferred thermoplastic polymer blends of the invention include blends of two or more thermoplastic copolymers, each comprising about 80 to 95 mole percent ethylene and about 5 to about 20 mole percent 1-butene. More preferred are blends comprising (i) a copolymer of about 91 mole percent ethylene and about 9 mole percent 1-butene (e.g., FLEXOMER™ DFDA 1137 polyolefin), and (ii) a copolymer of about 80 mole percent ethylene and about 20 mole percent 1-butene (e.g., FLEXOMER™ GERS 1085 NT polyolefin). Blends comprising one part by weight of component (i) and about 0.25 to about 4 parts by weight of component (ii) are particularly preferred, especially for use in a dynamic seal and in a pressurized system, e.g., in a metered-dose inhaler.

The polymer blends of the invention can also comprise minor amounts of conventional polymer additives such as processing aids, colorants, lubricants, and talc.

As illustrated in the TABLES below, some of the seal materials and sealing members of the invention are superior to others for use in the dynamic seal of a pressurized aerosol container. Those seal materials that are less than optimal for use in the exemplified systems can nonetheless find use, e.g., in connection with a different general type of drug or a different valve stem than exemplified, as a static seal in a pressurized system, or in a non-pressurized system having a dynamic seal. The TABLES below occasionally contain data that appear somewhat inconsistent with other data (e.g., a single very high standard deviation as in TABLE 17). These aberrant results are generally attributable to failure of one or two vials in the test group.

- 8 -

The device of the invention will be described with reference to the Drawing. FIG. 1 shows device 10 comprising valve stem 12, casing member 14, and diaphragm 16. The casing member has walls defining casing aperture 18, and the diaphragm has walls defining diaphragm aperture 17. The valve stem passes through and is in slidable sealing engagement with the diaphragm aperture. The diaphragm is also in sealing engagement with casing member 14. Diaphragm 16 represents a thermoplastic elastomeric sealing member of the invention.

The illustrated embodiment is a device for use with pharmaceutical formulations. The diaphragm in the illustrated embodiment is of a thickness sufficient to form an effective seal with the casing member, preferably about 0.005 inch to about 0.050 inch. It has an outside diameter of about 0.340 inch, and an inside diameter sufficient to form an effective seal with the valve stem. As valve stems having an outside diameter of about 0.110 inch are commonly used, suitable diaphragm inside diameter can be in the range of about 0.080 inch to about 0.105 inch. Diaphragm dimensions suitable for use with other general types of devices can be easily selected by those skilled in the art.

Valve stem 12 is in slidable engagement with diaphragm aperture 17. Helical spring 20 holds the valve stem in an extended closed position as illustrated in FIG. 1. Valve stem 12 has walls defining orifice 22 which communicates with exit chamber 24 in the valve stem. The valve stem also has walls defining channel 26.

In the illustrated embodiment casing member 14 comprises mounting cup 28 and canister body 30 and defines formulation chamber 32. The illustrated embodiment further comprises tank seal 34 having walls defining tank seal aperture 35, and metering tank 36 having inlet end 38, inlet aperture 40, and outlet end

42. The metering tank also has walls defining metering chamber 44 of predetermined volume (e.g., 50 μ L). Outlet end 42 of metering tank 36 is in sealing engagement with diaphragm 16, and valve stem 12 passes through inlet aperture 40 and is in slidable engagement with tank seal 34.

When device 10 is intended for use with a suspension aerosol formulation it further comprises retaining cup 46 fixed to mounting cup 28 and having walls defining retention chamber 48 and aperture 50. When intended for use with a solution aerosol formulation retaining cup 46 is optional. Also illustrated in device 10 is sealing member 52 in the form of an O-ring that substantially seals formulation chamber 32 defined by mounting cup 28 and canister body 30. Sealing member 52 preferably comprises the elastomeric copolymer described above.

Operation of device 10 is illustrated in FIGS. 1 and 2. In FIG. 1, the device is in the extended closed position. Aperture 50 allows open communication between retention chamber 48 and formulation chamber 32, thus allowing the aerosol formulation to enter the retention chamber. Channel 26 allows open communication between the retention chamber and metering chamber 44 thus allowing a predetermined amount of aerosol formulation to enter the metering chamber through inlet aperture 40. Diaphragm 16 seals outlet end 42 of the metering tank.

FIG. 2 shows device 10 in the compressed open position. As valve stem 12 is depressed channel 26 is moved relative to tank seal 34 such that inlet aperture 40 and tank seal aperture 35 are substantially sealed, thus isolating a metered dose of formulation within metering chamber 44. Further depression of the valve stem causes orifice 22 to pass through aperture 18 and into the metering chamber, whereupon the metered dose is exposed to ambient pressure. Rapid vaporization of the propellant causes the metered dose

- 10 -

to be forced through the orifice, and into and through exit chamber 24. Device 10 is commonly used in combination with an actuator that facilitates inhalation of the resulting aerosol by a patient.

5 A particularly preferred device of the invention is a metered dose configuration substantially as described above and illustrated in the Drawing. Other particular configurations, metered dose or otherwise, are well known to those skilled in the art
10 are suitable for use with the sealing members of this invention. For example the devices described in U.S. Pat. Nos. 4,819,834 (Thiel), 4,407,481 (Bolton), 3,052,382 (Gawthrop), 3,049,269 (Gawthrop), 2,980,301 (DeGorter), 2,968,427 (Meshberg), 2,892,576 (Ward),
15 2,886,217 (Thiel), and 2,721,010 (Meshberg) (all incorporated herein by reference) involve a valve stem, a diaphragm, and a casing member in the general relationship described herein. Generally any and all sealing members (such as diaphragms, seals, and
20 gaskets) that serve to minimize and/or prevent escape of components, especially propellant, from such assemblies can comprise the above described thermoplastic elastomer.

 The devices, sealing members, and polymer
25 blends of the invention can be used in connection with aerosol formulations involving propellants such as fluorotrichloromethane, dichlorodifluoromethane, and 1,2-dichlorotetrafluoroethane. However, this invention finds particular use with aerosol formulations
30 involving a propellant comprising HFC-134a or HFC-227. Any such formulation can be used. Pharmaceutical formulations are preferred.

 Preferred pharmaceutical formulations generally comprise HFC-134a, HFC-227, or a mixture
35 thereof in an amount effective to function as an aerosol propellant, a drug having local or systemic action and suitable for use by inhalation, and any optional formulation excipients. Exemplary drugs

having local effect in the lung include bronchodilators such as albuterol, formoterol, pirbuterol, and salmeterol, and pharmaceutically acceptable salts and derivatives thereof, and steroids such as

5 beclomethasone, fluticasone, and flunisolide, and pharmaceutically acceptable salts, derivatives, solvates, and clathrates thereof. Exemplary drugs having systemic effect include peptides such as insulin, calcitonin, interferons, colony stimulating

10 factors, and growth factors.

The drug is present in the formulation in an amount sufficient to provide a predetermined number of therapeutically effective doses by inhalation, which can be easily determined by those skilled in the art

15 considering the particular drug in the formulation. Optional excipients include cosolvents (e.g., ethanol, water) and surfactants (e.g., oleic acid, sorbitan esters, polyoxyethylenes, glycols) and others known to those skilled in the art.

20 A particularly preferred formulation comprises, by weight, 0.40% albuterol sulfate, 0.48% oleic acid, 14.26% absolute ethanol, and 84.86% HFC-134a. Another preferred formulation comprises, by weight, 0.337% beclomethasone dipropionate, 8.0%

25 absolute ethanol, and 91.663% HFC-134a. Yet another preferred formulation comprises, by weight, 0.084% of beclomethasone dipropionate, 8.0% absolute ethanol, and 91.916% HFC-134a.

30 Blend Preparation

Polymer blends of the invention, from which sealing members of the invention can be made, can be prepared by conventional polymer blending techniques well known to those skilled in the art. Those blends

35 exemplified herein were prepared as follows:

- 12 -

Small Scale Compounding

Selected quantities of the blend components are added to a heated 100 mL bowl in a BRABENDER™ laboratory mixer equipped with high shear mixing shafts. The components are mixed under temperature, speed, and time conditions selected according to the characteristics of the components of the blend. After mixing the mixing head is operated in reverse in order to expel the hot, mixed blend, which is compression molded as described below.

Large Scale Compounding

Selected quantities of the blend components are fed at room temperature into a APV Model 2030 TC twin screw extruder via feeders that are calibrated to match the extrusion rate.

Screw speed and extruder temperature are selected according to the characteristics of the components of the blend. The melt is extruded through a 0.63cm (0.25 inch) strand die having two strand openings. The strands are fed through a water bath, dried, and pelletized with a BERLYN™ Model Pe 112 chopper. The pellets are dried in trays for 1-3 days at about 50°C and extruded into a sheet as described below.

Diaphragm Preparation

Diaphragms of the invention can be prepared by conventional techniques known to those skilled in the art, such as compression molding, extrusion, and injection molding. Those diaphragms exemplified herein were prepared according to the general methods set forth below:

Compression Molding

An amount of a selected elastomer sufficient to provide a compression molded sheet of the desired thickness is compression molded between

appropriately spaced aluminum press plates in a CARVERTM Laboratory Press Model 2696 (Fred S. Carver, Inc., Menomonie Falls, Wisconsin) at elevated temperature (e.g., about 150°C) and pressure (e.g., 170 kPa) and
5 for a time sufficient to form a molded sheet. The press is then cooled until the mold plates can be handled. The compression molded sheet is removed from the mold and hand punched with a die of the desired size to afford a diaphragm of the invention.

10

Extrusion

A sample of a selected elastomer is fed into the feed throat of a Haake RHEOCORTTM single-screw extruder fitted with a Haake RHEOMIXTM three-zone
15 extruder head and equipped with a 1.9 cm (0.75 inch) diameter screw having a 3:1 pitch and a length to diameter ratio of 25:1. Appropriate screw speed and operating temperatures are selected according to the characteristics of the selected elastomer. The melt is
20 extruded through a flat film die, fitted with a shim to provide the desired opening, and over a cooled chrome roller. The thickness of the resulting sheet is controlled by appropriate adjustment of screw speed and speed of the cooled roller. Diaphragms of the
25 invention were hand cut from the sheet with a die of appropriate size.

Injection Molding

The selected elastomer is fed into the feed
30 throat of a Van Dorn 75 ton injection molding machine equipped with a 5 ounce barrel. Operating conditions are selected according to the characteristics of the selected elastomer. The melt is injected into a mold having cavity dimensions appropriate to provide the
35 desired sealing member. Cooling and opening of the mold affords the sealing member.

- 14 -

Test Methods

Sealing members were tested as follows:

Leak Rate

- 5 Aerosol canister bodies (10 mL) are filled with an aerosol formulation and fitted with a metered dose valve substantially as described and illustrated above and comprising a diaphragm of a selected size and material. The valve is actuated several times in
- 10 order to assure its function. The mass of the filled device is measured. The filled device is allowed to stand in an upright position under the indicated conditions (30°C unless otherwise indicated) for a period of time, after which time mass is again
- 15 measured. The loss of mass over time is extrapolated to one year and reported in mg/year.

Valve Delivery

- The mass of a filled device is measured.
- 20 The device is then inverted and actuated one time. Mass is again determined and the valve delivery is recorded as the difference.
- The formulations used in the TABLES below in order to demonstrate the invention are as follows,
- 25 wherein all parts and percentages are by weight:

Formulation	Albuterol Sulfate (%)	Beclomethasone Dipropionate (%)	Oleic Acid (%)	Ethanol (%)	HFC 134a (%)
A1	0.5	---	0.1	15	84.4
A2	0.47	---	0.097	14.24	85.2
A3	0.4	---	0.5	15	84.1
A4	0.8	---	0.5	15	83.7
A5	1.2	---	0.5	15	83.3
A6	0.8	---	0.5	14.9	83.8
B1	---	0.164	---	5.87	93.96
B2	---	0.166	---	6.04	93.78
B3	---	0.44	---	15	84.56
D	---	---	0.5	15.0	84.5
	Pirbuterol Acetate				HFC-227
P	0.89	---	---	10.0	89.11
	Albuterol Sulfate				HFC-227
A7	0.4	---	---		99.6

- 16 -

Diaphragms of FLEXOMER™ DEFD 8923 NT polyolefin were incorporated in a device substantially as described and illustrated above, and tested alongside devices comprising a neoprene diaphragm or a
5 butadiene-acrylonitrile "buna" resin diaphragm. Results are shown in TABLE 1 below wherein "RH" designates relative humidity.

TABLE 1 - LEAK RATE AND VALVE DELIVERY

Diaphragm Material	Formulation	Storage Condition	Time (Weeks)	N ²	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
Buna	A5	30°C	0	25/15	---	46.46 ± 8.52
			4	"	451 ± 71	48.90 ± 1.11
			12	"	526 ± 76	49.64 ± 0.71
Neoprene	A5	30°C	0	25/15	---	55.61 ± 0.69
			4	"	331 ± 54	55.31 ± 0.69
			12	"	395 ± 55	54.91 ± 0.92
DEFD 8923 NT	A6	30°C	0	24/24	---	55.05 ± 1.64
			1	"	99 ± 17	55.09 ± 0.85
			2	"	135 ± 14	55.02 ± 1.50
			4	"	185 ± 11	54.28 ± 1.29
DEFD 8923 NT	A6	40°C 85% RH	0	24/24	---	54.07 ± 3.48
			1	"	192 ± 17	54.20 ± 2.92
			2	"	288 ± 13	55.32 ± 1.03
			4	"	384 ± 12	54.54 ± 2.47
DEFD 8923 NT	B3	30°C	0	24/24	---	57.39 ± 1.15
			1	"	108 ± 15	57.31 ± 0.79
			2	"	160 ± 13	57.08 ± 1.08
			4	"	223 ± 12	57.20 ± 0.89
DEFD 8923 NT	B3	40°C 85% RH	0	24/24	---	57.43 ± 1.03
			1	"	286 ± 39	58.09 ± 2.52
			2	"	392 ± 34	58.78 ± 2.66
			4	"	491 ± 31	59.64 ± 3.40

Table 1 - Continued

1	Buna and neoprene diaphragms from American Gasket and Rubber, Chicago, Illinois. "DEFD 8923 NT" designates FLEXOMER™ DEFD 8923 NT polyolefin. All DEFD 8923 NT diaphragms were 0.035 inch thick with 0.095 inch inside diameter and 0.34 inch outside diameter. The buna and neoprene diaphragms were 0.038 inch thick with a 0.093 inch inside diameter and a 0.340 inch outside diameter. The valve stem had a 0.110 inch outside diameter.
2	N is the number of vials per group. The first number of the pair is the number of valves whose individual measurements were averaged to give the reported leak rate. The second number of the pair is the number of individual measurements which were averaged to give the reported valve delivery.

The results in TABLE 1 show that, with the designated formulations using HFC-134a as the propellant, leak rates are substantially lower in the devices comprising the diaphragm of the invention than
5 in the devices comprising diaphragms of materials that are commonly used in commercially available metered dose aerosol devices. Only under conditions of thermal stress (40°C, 85% RH) did the devices of the invention have leak rates comparable to those of the comparative
10 devices tested at 30°C. Furthermore, valve delivery is more precise and more constant over time with devices of the invention than in the comparative devices of the prior art. Moreover, while the valves in the comparative devices often stuck, paused, or dragged
15 during actuation, the valves in the devices of the invention generally exhibited smooth operation over the duration of the study.

Diaphragms of the invention of the specified composition and having a thickness of 0.035
20 inch, an outside diameter of 0.34 inch, and various inside diameters were tested with HFC-134a alone and with a model formulation (containing HFC-134a, ethanol, and a surfactant) in devices having either stainless steel ("ss") or DELRIN™ acetal resin (DuPont,
25 "plastic") valve stems having a diameter of 0.110 inch. Results are shown in TABLE 2 (FLEXOMER™ DEFD 8923 NT polyolefin), TABLE 3 (FLEXOMER™ DFDA 1137 polyolefin), and TABLE 4 (FLEXOMER™ DFDA 1138 polyolefin) below, wherein each entry represents the mean of seven
30 independent determinations.

Table 2

LEAK RATE AND VALVE DELIVERY WITH STAINLESS STEEL AND PLASTIC VALVE STEMS
USING FLEXOMER™ 8923 NT POLYOLEFIN DIAPHRAGMS HAVING VARIOUS INSIDE DIAMETERS

Formulation	ID (in)	Stem	Time (Weeks)	Leak Rate (mg/yr) \pm SD	Valve Delivery (mg/actuation) \pm SD
134a	0.080	ss plastic	0	---	86.90 \pm 94.55
			5	34 \pm 25	64.30 \pm 1.30
			0	---	61.86 \pm 2.80
			5	26 \pm 12	63.50 \pm 0.62
134a	0.085	ss plastic	0	---	64.87 \pm 7.61
			5	30 \pm 17	61.34 \pm 6.19
			0	---	63.29 \pm 0.60
			5	26 \pm 13	63.27 \pm 0.40
134a	0.090	ss plastic	0	---	64.44 \pm 1.55
			5	26 \pm 3	65.76 \pm 2.30
			0	---	63.63 \pm 0.83
			5	40 \pm 27	63.17 \pm 0.72
134a	0.095	ss plastic	0	---	66.66 \pm 1.11
			5	25 \pm 2	68.03 \pm 1.33
			0	---	64.61 \pm 0.98
			5	24 \pm 3	64.63 \pm 1.11

Table 2 - continued

Formulation	ID (in)	Stem	Time (Weeks)	Leak Rate (mg/Yr) \pm SD	Value Delivery (mg/actuation) \pm SD
134a	0.100	ss plastic	0	---	58.79 \pm 19.27
			5	27 \pm 4	67.27 \pm 0.99
			0	---	65.07 \pm 0.49
			5	33 \pm 22	65.13 \pm 0.73
134a	0.105	ss plastic	0	---	65.34 \pm 1.80
			5	26 \pm 0.81	66.84 \pm 0.81
			0	---	65.13 \pm 0.79
			5	27 \pm 4	65.14 \pm 1.85
D	0.080	ss plastic	0	---	61.26 \pm 1.33
			5	147 \pm 13	61.61 \pm 1.26
			0	---	60.46 \pm 0.80
			5	143 \pm 14	59.73 \pm 0.73
D	0.085	ss plastic	0	---	62.43 \pm 1.00
			5	140 \pm 19	62.71 \pm 1.11
			0	---	61.21 \pm 0.75
			5	138 \pm 6	60.46 \pm 0.74
D	0.090	ss plastic	0	---	61.81 \pm 0.83
			5	149 \pm 20	62.07 \pm 0.87
			0	---	61.23 \pm 0.56
			5	140 \pm 12	60.61 \pm 0.41

Table 2 - continued

Formulation	ID (in)	Stem	Time (Weeks)	Leak Rate (mg/yr) \pm SD	Valve Delivery (mg/actuation) n) \pm SD
D	0.095	ss plastic	0	---	63.24 \pm 0.73
			5	154 \pm 8	63.79 \pm 0.81
			0	---	62.26 \pm 0.59
			5	165 \pm 12	62.07 \pm 0.49
D	0.100	ss plastic	0	---	62.99 \pm 0.94
			5	150 \pm 10	63.61 \pm 0.97
			0	---	62.21 \pm 1.03
			5	167 \pm 14	62.39 \pm 0.67
D	0.105	ss plastic	0	---	63.79 \pm 0.66
			5	163 \pm 7	64.69 \pm 0.64
			0	---	61.66 \pm 1.82
			5	171 \pm 9	61.77 \pm 1.03

TABLE 3

LEAK RATE AND VALVE DELIVERY WITH STAINLESS STEEL AND PLASTIC VALVE STEMS
USING FLEXOMER™ 1137 POLYOLEFIN DIAPHRAGMS HAVING VARIOUS INSIDE DIAMETERS

Formulation	ID (in)	Stem	Time (Weeks)	Leak Rate (mg/yr) \pm SD	Valve Delivery (mg/actuation) \pm SD
134a	0.080	ss	0	---	63.77 \pm 9.37
			5	28.4 \pm 3.4	67.14 \pm 0.83
		plastic	0	---	62.73 \pm 3.40
			5	28.6 \pm 6.7	61.91 \pm 3.21
134a	0.085	ss	0	---	67.57 \pm 17.25
			5	30.7 \pm 6.8	67.77 \pm 3.59
		plastic	0	---	61.41 \pm 4.20
			5	29.6 \pm 11.0	60.90 \pm 7.20
134a	0.090	ss	0	---	58.90 \pm 19.00
			5	34.6 \pm 6.7	66.80 \pm 0.88
		plastic	0	---	62.07 \pm 3.78
			5	27.7 \pm 4.2	61.23 \pm 6.49
134a	0.095	ss	0	---	59.83 \pm 15.34
			5	25.9 \pm 5.9	66.67 \pm 0.67
		plastic	0	---	65.01 \pm 0.95
			5	32.8 \pm 18.5	65.16 \pm 0.72

TABLE 3 - continued

Formulation	ID (in)	Stem	Time (Weeks)	Leak Rate (mg/Yr) \pm SD	Valve Delivery (mg/actuation) \pm SD
D	0.080	ss	0	---	59.34 \pm 4.75
			5	163 \pm 30.8	62.84 \pm 0.53
		plastic	0	---	56.31 \pm 5.38
			5	197 \pm 34.1	61.04 \pm 0.26
D	0.085	ss	0	---	61.83 \pm 1.64
			5	179 \pm 61.8	63.13 \pm 0.87
		plastic	0	---	59.59 \pm 2.41
			5	156 \pm 16.4	60.74 \pm 0.37
D	0.090	ss	0	---	60.83 \pm 2.39
			5	169 \pm 40.8	61.90 \pm 2.31
		plastic	0	---	59.04 \pm 1.31
			5	225 \pm 31.0	60.10 \pm 2.66
D	0.095	ss	0	---	59.59 \pm 4.07
			5	210 \pm 53.0	60.00 \pm 3.66
		plastic	0	---	54.99 \pm 5.41
			5	243 \pm 35.9	56.20 \pm 1.58

TABLE 3

LEAK RATE AND VALVE DELIVERY WITH STAINLESS STEEL AND PLASTIC VALVE STEMS
USING FLEXOMER™ 1137 POLYOLEFIN DIAPHRAGMS HAVING VARIOUS INSIDE DIAMETERS

TABLE 3 - continued				
Formulation	ID (in)	Stem	Time (Weeks)	Leak Rate (mg/yr) ± SD
D	0.100	ss	0	---
			5	187 ± 12.9
		plastic	0	---
			5	282 ± 118
D	0.105	ss	0	---
			5	200 ± 11.9
		plastic	0	---
			5	232 ± 30.8
				61.49 ± 1.37
				61.41 ± 1.25
				54.89 ± 3.36
				56.14 ± 1.95
				50.81 ± 5.07
				53.00 ± 3.28
				48.43 ± 2.57
				48.51 ± 1.02

TABLE 4
LEAK RATE AND VALVE DELIVERY WITH STAINLESS STEEL AND PLASTIC VALVE STEMS
USING FLEXOMER™ 1138 POLYOLEFIN DIAPHRAGMS HAVING VARIOUS INSIDE DIAMETERS

Formulation	ID (in)	Stem	Time (Weeks)	Leak Rate (mg/yr) \pm SD	Valve Delivery (mg/actuation) \pm SD
134a	0.080	ss	0	---	66.17 \pm 56.10
			5	16.4 \pm 2.51	63.03 \pm 20.22
		plastic	0	---	62.27 \pm 6.85
			5	14.9 \pm 1.8	64.89 \pm 1.30
134a	0.085	ss	0	---	59.77 \pm 18.00
			5	36.8 \pm 44.4	64.77 \pm 17.07
		plastic	0	---	69.40 \pm 15.00
			5	15.0 \pm 3.9	65.26 \pm 1.07
134a	0.090	ss	0	---	52.64 \pm 18.28
			5	45.7 \pm 43.5	68.67 \pm 2.12
		plastic	0	---	57.86 \pm 15.78
			5	14.8 \pm 3.6	70.34 \pm 8.47
134a	0.095	ss	0	---	57.57 \pm 17.59
			5	22.5 \pm 7.3	68.43 \pm 1.07
		plastic	0	---	64.84 \pm 1.69
			5	14.5 \pm 3.4	65.97 \pm 2.67
134a	0.100	ss	0	---	59.70 \pm 20.32
			5	20.3 \pm 7.3	67.59 \pm 1.95
		plastic	0	---	64.79 \pm 0.61
			5	21.1 \pm 18.8	65.53 \pm 0.72

Table 4 - continued

134a	0.105	ss	Time (Weeks)	Leak Rate (mg/yr) \pm SD	Valve Delivery (mg/actuation) \pm SD
		ss	0	---	65.64 \pm 0.90
		plastic	5	23.7 \pm 3.0	67.34 \pm 0.80
			0	---	65.11 \pm 1.67
			5	17.4 \pm 3.4	68.56 \pm 3.86
Formulation	ID (in)	Stem	Time (Weeks)	Leak Rate (mg/yr) \pm SD	Valve Delivery (mg/actuation) \pm SD
D	0.080	ss	0	---	60.23 \pm 0.57
		plastic	5	187 \pm 14.3	60.90 \pm 0.63
			0	---	58.41 \pm 0.52
			5	204 \pm 6.2	50.16 \pm 22.12
D	0.085	ss	0	---	60.74 \pm 1.12
		plastic	5	178 \pm 5.4	61.30 \pm 0.92
			0	---	58.43 \pm 0.45
			5	220 \pm 30.4	59.04 \pm 2.10
D	0.090	ss	0	---	60.11 \pm 1.36
		plastic	5	237 \pm 42.8	61.04 \pm 1.39
			0	---	56.87 \pm 0.79
			5	258 \pm 24.5	56.36 \pm 1.01
D	0.095	ss	0	---	58.37 \pm 5.54
		plastic	5	252 \pm 40.8	60.69 \pm 1.98
			0	---	52.76 \pm 6.49
			5	270 \pm 21.6	55.26 \pm 1.52

TABLE 4 - continued

Formulation	ID (in)	Stem	Time (Weeks)	Leak Rate (mg/Yr) \pm SD	Valve Delivery (mg/actuation) \pm SD
D	0.100	SS plastic	0	---	58.66 \pm 0.45
			5	217 \pm 13.3	58.60 \pm 0.60
			0	---	56.97 \pm 1.37
			5	288 \pm 74.6	56.66 \pm 1.87
D	0.105	SS plastic	0	---	58.31 \pm 0.85
			5	243 \pm 16.3	58.51 \pm 0.85
			0	---	57.40 \pm 0.98
			5	251 \pm 11.0	56.61 \pm 0.52

The results in TABLES 2, 3, and 4 show that diaphragms of the invention having various inside diameters afford low leak rates and reproducible valve delivery with stainless steel ("ss") and DELRINTM acetal resin ("plastic") valve stems when used with the designated formulations. Leak rate results with the ethanol-containing formulation, while not as low as with only HFC-134a, compare favorably to the data in TABLE 1 involving buna and neoprene diaphragms. Furthermore, the valves in the devices of the invention generally exhibited smooth operation over the duration of the study.

Diaphragms of the invention prepared from FLEXOMERTM DEFD 8923 NT polyolefin and having an inside diameter of 0.090 inch and various specified thicknesses were tested with HFC-134a alone or with a model formulation (containing HFC-134a, ethanol, and a surfactant) in devices comprising either stainless steel ("ss") or DELRINTM acetal resin ("plastic") valve stems. Results are shown in TABLE 5 below, wherein each entry represents the mean of 7 independent determinations.

TABLE 5
LEAK RATE USING FLEXOMER™ 8923 NT POLYOLEFIN DIAPHRAGMS OF VARIOUS THICKNESSES

Formulation	Thickness (in)	Stem	Time (Weeks)	Leak Rate (mg/yr) \pm SD
134a	0.038	ss plastic	0	---
			5	25.8 \pm 4.0
			0	---
			5	24.6 \pm 3.9
134a	0.035	ss plastic	0	---
			5	27.3 \pm 4.3
			0	---
			5	48.5 \pm 66.0
134a	0.029	ss plastic	0	---
			5	24.5 \pm 2.0
			0	---
			5	22.2 \pm 3.5
134a	0.025	ss plastic	0	---
			5	24.5 \pm 6.5
			0	---
			5	24.5 \pm 11
134a	0.020	ss plastic	0	---
			5	21.9 \pm 2.5
			0	---
			5	20.0 \pm 1.6

TABLE 5 - continued

Formulation	Thickness (in)	Stem	Time (Weeks)	Leak Rate (mg/Yr) \pm SD
134a	0.015	ss plastic	0	---
			5	22.2 \pm 2.6
			0	---
			5	50.0 \pm 2.6
134a	0.010	ss plastic	0	---
			5	46.7 \pm 38.7
			0	---
			5	16.5 \pm 2.3
D	0.038	ss plastic	0	---
			5	200 \pm 17
			0	---
			5	217 \pm 14
D	0.035	ss plastic	0	---
			5	185 \pm 8.7
			0	---
			5	209 \pm 12
D	0.029	ss plastic	0	---
			5	182 \pm 2.5
			0	---
			5	201 \pm 12

TABLE 5 - continued

Formulation	Thickness (in)	Stem	Time (Weeks)	Leak Rate (mg/yr) \pm SD
D	0.025	ss plastic	0	---
			5	176 \pm 6.4
			0	---
			5	210 \pm 4.8
D	0.020	ss plastic	0	---
			5	190 \pm 6.5
			0	---
			5	207 \pm 7.4
D	0.015	ss plastic	0	---
			5	182 \pm 7.8
			0	---
			5	196 \pm 6.4
D	0.010	ss plastic	0	---
			5	180 \pm 5.4
			0	---
			5	201 \pm 20

The results in TABLE 5 show that with the designated formulations leak rate is lower in devices comprising a diaphragm of the invention than in devices such as those tested in connection with TABLE 1 above
5 comprising a buna or neoprene diaphragm. TABLE 5 also shows that relatively thin diaphragms can be used with little or no loss of performance.

In the TABLES that follow, the inside diameter of the diaphragms (ID) is given in thousandths
10 of an inch, "pl" represents a valve stem made of DELRIN™ acetal resin (DuPont) having a diameter of 0.110 inch, and "N" refers to the number of independent determinations used in calculating the leak rate and valve delivery values.

15 Diaphragms of the invention were prepared by compression molding, injection molding, and extrusion from FLEXOMER™ GERS 1085 NT polyolefin and tested with the formulations indicated in TABLES 6-8 below.

TABLE 6
COMPRESSION MOLDED FLEXOMER™ GERS 1085 NT POLYOLEFIN

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A1	80	SS	0 6	14	--- 243 ± 10	56.81 ± 0.74 57.18 ± 0.82
	85	SS	0 6	14	--- 247 ± 10	55.94 ± 3.64 58.74 ± 1.26
	90	SS	0 6	14	--- 240 ± 9	58.09 ± 6.45 59.74 ± 2.92
	95	SS	0 6	14	--- 231 ± 12	58.40 ± 0.95 59.33 ± 1.44
	100	SS	0 6	14	--- 227 ± 8	58.41 ± 1.46 60.40 ± 2.78
	105	SS	0 6	14	--- 224 ± 8	55.94 ± 7.25 62.52 ± 3.77
	80	pl	0 6	14	--- 270 ± 6	55.91 ± 1.48 55.62 ± 0.68
	85	pl	0 6	14	--- 270 ± 11	54.22 ± 4.63 56.71 ± 2.22
	90	pl	0 6	14	--- 265 ± 16	57.42 ± 4.56 58.67 ± 2.13

TABLE 6 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	95	p1	0 6	14	--- 260 ± 8	56.10 ± 4.14 58.67 ± 1.72
	100	p1	0 6	14	--- 256 ± 14	58.73 ± 3.30 60.96 ± 3.72
	105	p1	0 6	14	--- 243 ± 11	57.96 ± 3.17 61.50 ± 1.35

TABLE 7
INJECTION MOLDED FLEXOMER™ GERS 1085 NT POLYOLEFIN

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A1	84	ss	0 6	10	--- 263 ± 8	57.70 ± 1.06 59.17 ± 1.12
	88	ss	0 6	10	--- 275 ± 10	56.51 ± 2.98 60.21 ± 2.34
	94	ss	0 6	10	--- 286 ± 12	58.87 ± 1.85 58.70 ± 0.64
	99	ss	0 6	10	--- 269 ± 11	58.12 ± 0.54 59.48 ± 2.75
	84	pl	0 6	10	--- 267 ± 9	55.49 ± 2.52 55.92 ± 1.81
	88	pl	0 6	10	--- 284 ± 11	56.33 ± 0.34 56.56 ± 0.24
B1	94	pl	0 6	10	--- 286 ± 10	56.21 ± 1.23 56.72 ± 0.42
	99	pl	0 6	10	--- 282 ± 11	55.35 ± 2.74 56.54 ± 0.99
	84	ss	0 6	10	--- 231 ± 16	62.18 ± 0.92 63.24 ± 1.26
	88	ss	0 6	10	--- 232 ± 11	61.93 ± 0.50 64.20 ± 3.20

TABLE 7 - continued						
Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	88	pl	0 6	10	--- 246 ± 10	60.29 ± 0.78 60.57 ± 0.45
	94	pl	0 6	10	--- 251 ± 10	60.75 ± 0.96 60.73 ± 0.64
	99	pl	0 6	10	--- 264 ± 22	59.43 ± 3.11 60.46 ± 0.45

TABLE 8
EXTRUDED FLEXOMER™ GERS 1085 NT POLYOLEFIN

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A2	80	ss	0 6	10	--- 279 ± 9	58.26 ± 2.17 57.76 ± 0.96
	85	ss	0 6	10	--- 274 ± 15	57.49 ± 2.24 57.99 ± 2.23
	90	ss	0 6	10	--- 274 ± 15	58.66 ± 1.91 58.01 ± 0.66
	95	ss	0 6	10	--- 282 ± 18	57.29 ± 2.97 58.30 ± 1.11
	100	ss	0 6	10	--- 284 ± 18	58.49 ± 1.64 58.16 ± 0.77
	105	ss	0 6	10	--- 307 ± 11	57.97 ± 1.40 57.99 ± 1.10
	80	pl	0 6	10	--- 270 ± 14	55.91 ± 0.69 55.50 ± 0.66
	85	pl	0 6	10	--- 275 ± 8	55.18 ± 1.41 55.25 ± 0.48
	90	pl	0 6	10	--- 277 ± 12	56.38 ± 0.66 55.54 ± 0.53
	95	pl	0 6	10	--- 284 ± 14	56.68 ± 0.71 55.67 ± 0.58

Table 8 - continued

	100	ss	0 6	10	--- 284 ± 18	58.49 ± 1.64 58.16 ± 0.77
	105	ss	0 6	10	--- 307 ± 11	57.97 ± 1.40 57.99 ± 1.10
	80	pl	0 6	10	--- 270 ± 14	55.91 ± 0.69 55.50 ± 0.66
	85	pl	0 6	10	--- 275 ± 8	55.18 ± 1.41 55.25 ± 0.48
	90	pl	0 6	10	--- 277 ± 12	56.38 ± 0.66 55.54 ± 0.53
	95	pl	0 6	10	--- 284 ± 14	56.68 ± 0.71 55.67 ± 0.58
	100	pl	0 6	10	--- 282 ± 13	56.37 ± 0.70 55.41 ± 0.51
	105	pl	0 6	10	--- 318 ± 25	56.38 ± 0.65 55.56 ± 0.64
A3	80	ss	0 6	10	--- 232 ± 18	58.35 ± 0.74 not measured
	85	ss	0 6	10	--- 233 ± 20	58.35 ± 1.00 57.96 ± 0.92

TABLE 8 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A3	90	ss	0 6	10	--- 247 ± 62	57.60 ± 2.61 57.85 ± 0.87
	95	ss	0 6	10	--- 226 ± 22	58.82 ± 0.73 58.41 ± 0.74
	100	ss	0 6	10	--- 231 ± 23	58.97 ± 0.83 58.59 ± 0.65
	105	ss	0 6	10	--- 253 ± 22	58.87 ± 1.02 not measured
	80	pl	0 6	10	--- 236 ± 13	55.98 ± 0.55 54.97 ± 0.35
	85	pl	0 6	10	--- 239 ± 15	56.17 ± 0.50 54.65 ± 0.72
	90	pl	0 6	10	--- 230 ± 9	56.27 ± 0.55 55.01 ± 0.58
	95	pl	0 6	10	--- 239 ± 20	56.78 ± 1.80 55.93 ± 0.52
	100	pl	0 6	10	--- 231 ± 11	57.38 ± 0.69 55.95 ± 0.74
	105	pl	0 6	10	--- 245 ± 16	57.34 ± 0.70 55.56 ± 0.49

TABLE 8 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
B2	80	SS	0 6	10	--- 157 ± 16	60.32 ± 3.80 62.60 ± 0.94
	85	SS	0 6	10	--- 190 ± 60	62.49 ± 1.02 63.34 ± 0.78
	90	SS	0 6	10	--- 153 ± 11	62.68 ± 0.89 63.16 ± 0.71
	95	SS	0 6	10	--- 156 ± 10	62.60 ± 0.66 64.36 ± 3.29
	100	SS	0 6	10	--- 155 ± 10	63.39 ± 2.36 65.12 ± 2.70
	105	SS	0 6	10	--- 155 ± 7	64.08 ± 1.67 64.39 ± 0.85
	80	pl	0 6	10	--- 158 ± 9	61.20 ± 3.22 59.90 ± 0.33
	85	pl	0 6	10	--- 156 ± 11	60.15 ± 1.02 60.05 ± 0.71
	90	pl	0 6	10	--- 158 ± 28	60.95 ± 2.00 60.14 ± 0.68
	95	pl	0 6	10	--- 158 ± 7	54.61 ± 19.10 60.94 ± 0.59

TABLE 8 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
B2	100	ss	0	10	---	63.39 \pm 2.36
			6		155 \pm 10	65.12 \pm 2.70
	105	ss	0	10	---	64.08 \pm 1.67
			6		155 \pm 7	64.39 \pm 0.85
	80	pl	0	10	---	61.20 \pm 3.22
			6		158 \pm 9	59.90 \pm 0.33
	85	pl	0	10	---	60.15 \pm 1.02
			6		156 \pm 11	60.05 \pm 0.71
	90	pl	0	10	---	60.95 \pm 2.00
			6		158 \pm 28	60.14 \pm 0.68
	95	pl	0	10	---	54.61 \pm 19.10
			6		158 \pm 7	60.94 \pm 0.59
	100	pl	0	10	---	61.05 \pm 1.37
			6		153 \pm 10	61.71 \pm 2.26
	105	pl	0	10	---	60.85 \pm 0.62
			6		154 \pm 9	60.71 \pm 0.66

The results in TABLES 6-8 show that these diaphragms of the invention exhibit acceptable leak rate and valve delivery variability when used with the indicated formulations, regardless of the method of
5 preparation or the valve stem material.

Diaphragms of the invention were prepared by injection molding and by compression molding from FLEXOMER™ DFDA 1137 NT 7 polyolefin and tested with the formulations indicated in TABLES 9A and 9B below.

TABLE 9 A
INJECTION MOLDED FLEXOMER™ DFDA 1137 NT 7 POLYOLEFIN

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A2	84	ss	0 6	10	--- 297 ± 41	61.51 ± 2.04 61.79 ± 1.78
	88	ss	0 6	10	--- 298 ± 35	59.56 ± 0.80 61.28 ± 3.39
	94	ss	0 6	10	--- 312 ± 18	61.57 ± 3.81 66.49 ± 7.58
	98	ss	0 6	10	--- 289 ± 17	61.88 ± 5.25 63.31 ± 7.20
	84	pl	0 6	10	--- 298 ± 32	60.88 ± 2.38 59.47 ± 1.12
	88	pl	0 6	10	--- 288 ± 35	59.68 ± 1.80 59.33 ± 1.25
	94	pl	0 6	10	--- 303 ± 23	59.14 ± 1.05 61.38 ± 4.29
	98	pl	0 6	10	--- 292 ± 16	58.81 ± 2.06 60.56 ± 1.75

TABLE 9 B
COMPRESSION MOLDED FLEXOMER™ DFDA 1137 NT 7 POLYOLEFIN

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A4	95	p1	0	24	---	53.14 ± 7.34
			2		198 ± 51	56.13 ± 0.99
			4		249 ± 50	54.71 ± 3.07
			8		296 ± 50	55.60 ± 1.55
			12		330 ± 52	53.96 ± 7.10
			24		361 ± 52	54.62 ± 5.58
B3	95	p1	0	24	---	56.09 ± 2.41
			2		221 ± 26	57.07 ± 1.27
			4		265 ± 27	56.67 ± 1.67
			8		311 ± 29	57.25 ± 1.61
			12		345 ± 31	57.32 ± 2.23
			24		373 ± 32	59.10 ± 3.22

- 46 -

The results in TABLES 9A and 9B show that these diaphragms of the invention exhibit acceptable leak rate (which increases over time) and valve delivery variability when used with the indicated formulations. Little difference is seen between valve stem types or between injection molded diaphragms and compression molded diaphragms. A similar increase in leak rate was observed over time when compression molded FLEXOMER™ DFDA 1138 NT polyolefin was used as the diaphragm material with formulations A4 and B3.

Diaphragms of the invention were prepared from FLEXOMER™ DFDA 1163 NT7 polyolefin and tested with the formulations indicated in TABLE 10 below.

TABLE 10
COMPRESSION MOLDED FLEXOMER™ DFDA 1163 NT 7 POLYOLEFIN

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A1	80	SS	0 6	14	--- 259 ± 9	60.09 ± 0.81 60.31 ± 0.68
	85	SS	0 6	14	--- 279 ± 14	60.28 ± 0.78 60.46 ± 0.86
	90	SS	0 6	14	--- 278 ± 17	60.31 ± 1.20 60.56 ± 0.90
	95	SS	0 6	14	--- 299 ± 20	59.44 ± 1.33 60.18 ± 0.94
	100	SS	0 6	14	--- 394 ± 341	59.64 ± 1.35 60.09 ± 1.15
	105	SS	0 6	14	--- 293 ± 22	60.01 ± 0.85 59.79 ± 0.76
	80	pl	0 6	14	--- 286 ± 72	58.96 ± 0.61 not measured
	85	pl	0 6	14	--- 275 ± 13	59.44 ± 0.56 58.07 ± 1.80
	90	pl	0 6	14	--- 295 ± 45	59.22 ± 0.65 58.51 ± 0.57
	95	pl	0 6	14	--- 300 ± 23	58.96 ± 0.65 58.34 ± 0.76

Table 10 - continued						
Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	100	p1	0 6	14	--- 315 ± 34	58.73 ± 0.70 58.73 ± 2.18
	105	p1	0 6	14	--- 899 ± 2183	58.19 ± 0.67 58.08 ± 1.43

- 49 -

The results in TABLE 10 show that these diaphragms of the invention exhibit higher but generally acceptable leak rates and valve delivery variability when used with the indicated formulations, regardless of valve stem type. However, increasing inside diameter appears to increase leak rate with the plastic valve stem.

Diaphragms of the invention were prepared from FLEXOMER™ DFDA 1164 NT7 polyolefin and tested with the formulations indicated in TABLES 11-13 below.

TABLE 11
COMPRESSION MOLDED FLEXOMER™ DFDA 1164 NT 7 POLYOLEFIN

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A1	80	ss	0 6	14	--- 421 ± 195	60.57 ± 0.62 60.74 ± 0.56
	85	ss	0 6	14	--- 338 ± 108	61.04 ± 0.99 61.30 ± 0.88
	90	ss	0 6	14	--- 357 ± 264	61.16 ± 0.77 58.94 ± 7.77
	95	ss	0 6	14	--- 628 ± 634	61.26 ± 0.73 61.74 ± 0.80
	100	ss	0 6	14	--- 458 ± 229	60.19 ± 0.65 60.93 ± 0.90
	105	ss	0 6	14	--- 478 ± 263	60.60 ± 0.52 60.90 ± 0.67
	80	pl	0 6	14	--- 276 ± 50	59.82 ± 0.92 59.23 ± 0.71
	85	pl	0 6	14	--- 264 ± 19	59.90 ± 0.78 59.44 ± 0.75
	90	pl	0 6	14	--- 262 ± 16	60.02 ± 1.04 59.64 ± 1.63
	95	pl	0 6	14	--- 268 ± 17	60.20 ± 1.05 59.76 ± 1.38

Table 11 - continued						
Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	100	pl	0 6	14	--- 380 ± 385	58.68 ± 1.74 58.69 ± 2.87
	105	pl	0 6	14	--- 308 ± 48	58.41 ± 1.94 59.73 ± 1.84

TABLE 12
INJECTION MOLDED FLEXOMER™ DFDA 1164 NT 7 POLYOLEFIN

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A1	84	SS	0 6	10	--- 305 ± 35	62.34 ± 2.83 69.99 ± 7.80
	88	SS	0 6	10	--- 301 ± 23	63.45 ± 4.87 69.30 ± 9.12
	94	SS	0 6	10	--- 304 ± 14	65.22 ± 6.21 69.09 ± 7.02
	99	SS	0 6	10	--- 308 ± 19	65.51 ± 5.42 81.53 ± 25.99
B1	84	pl	0 6	10	--- 428 ± 334	62.62 ± 2.15 60.99 ± 4.02
	88	pl	0 6	10	--- 350 ± 110	60.67 ± 2.76 59.67 ± 3.38
	94	pl	0 6	10	--- 582 ± 397	64.18 ± 5.65 60.67 ± 2.30
	99	pl	0 6	10	--- 327 ± 23	62.19 ± 3.86 not measured
	84	SS	0 6	10	--- 284 ± 22	69.83 ± 6.84 76.36 ± 8.94
	88	SS	0 6	10	--- 260 ± 33	70.33 ± 5.42 74.86 ± 6.29

TABLE 12 - continued						
Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	94	ss	0 6	10	---- 273 ± 33	67.83 ± 4.70 71.89 ± 4.32
	99	ss	0 6	10	---- 255 ± 19	69.73 ± 4.97 81.76 ± 8.71
B1	84	pl	0 6	10	---- 286 ± 29	69.04 ± 5.87 69.72 ± 6.85
	88	pl	0 6	10	---- 629 ± 1064	68.16 ± 6.78 69.30 ± 6.70
	94	pl	0 6	10	---- 292 ± 38	66.15 ± 2.89 67.20 ± 8.22
	99	pl	0 6	10	---- 491 ± 654	69.45 ± 7.39 70.29 ± 7.77

TABLE 13
EXTRUDED FLEXOMER™ DFDA 1164 NT 7 POLYOLEFIN

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
B2	80	ss	0 6	10	---	66.90 ± 0.37 67.05 ± 0.42
	85	ss	0 6	10	---	65.26 ± 1.26 63.81 ± 1.61
	90	ss	0 6	10	---	65.10 ± 0.96 66.55 ± 0.76
	95	ss	0 6	10	---	65.67 ± 1.30 66.53 ± 0.90
	100	ss	0 6	10	---	66.58 ± 2.91 66.39 ± 1.54
	105	ss	0 6	10	---	65.03 ± 2.90 67.02 ± 1.61
	80	pl	0 6	10	---	64.77 ± 2.20 64.29 ± 1.45
	85	pl	0 6	10	---	63.55 ± 1.17 63.53 ± 1.07
	90	pl	0 6	10	---	63.40 ± 0.57 64.45 ± 1.60
	95	pl	0 6	10	---	63.43 ± 0.63 64.70 ± 1.85

TABLE 13 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/Yr)	Valve Delivery (mg/actuation)
	100	pl	0 6	10	--- 341 ± 388	63.59 ± 0.71 66.27 ± 4.49
	100	pl	0 6	10	--- 226 ± 29	63.17 ± 0.85 69.72 ± 8.48

- 56 -

The results in TABLES 11-13 show that these diaphragms of the invention exhibit higher but generally suitable leak rate and valve delivery variability when used with the indicated formulations.

- 5 Valve delivery is least variable for the compression molded diaphragms. With the extruded diaphragms leak rate with the beclomethasone dipropionate formulation is improved when a plastic valve stem is used.

- 10 Diaphragms of the invention were prepared from FLEXOMER™ DEFD 1491 NT7 polyolefin and tested with the formulations indicated in TABLE 14 below.

TABLE 14
COMPRESSION MOLDED FLEXOMER™ DEFD 1491 NT 7 POLYOLEFIN

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A1	80	ss	0 6	14	--- 275 ± 26	58.69 ± 1.15 58.86 ± 1.46
	85	ss	0 6	14	--- 277 ± 23	59.00 ± 0.83 59.42 ± 0.75
	90	ss	0 6	14	--- 268 ± 20	59.13 ± 0.97 59.59 ± 0.96
	95	ss	0 6	14	--- 284 ± 26	58.95 ± 0.91 59.50 ± 0.79
	100	ss	0 6	14	--- 279 ± 19	59.07 ± 0.79 59.04 ± 1.08
	105	ss	0 6	14	--- 272 ± 18	59.06 ± 0.53 59.51 ± 1.18
	80	pl	0 6	14	--- 267 ± 10	57.39 ± 2.06 57.33 ± 1.33
	90	pl	0 6	14	--- 283 ± 28	58.22 ± 0.54 57.66 ± 0.64
	90	pl	0 6	14	--- 269 ± 8	58.35 ± 0.69 56.83 ± 3.43
	95	pl	0 6	14	--- 276 ± 13	58.02 ± 0.84 57.68 ± 0.58

TABLE 14						
Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	100	pl	0 6	14	--- 281 ± 17	57.72 ± 0.74 57.26 ± 0.88
	105	pl	0 6	14	--- 276 ± 19	58.29 ± 0.65 56.21 ± 3.22

The results in TABLE 14 show that these diaphragms of the invention exhibit acceptable leak rates and valve delivery variability when used with the indicated formulations.

- 5 Diaphragms of the invention were prepared from FLEXOMER™ DFDA 9020 NT7 polyolefin and tested with the formulations indicated in TABLES 15-16.

TABLE 15
EXTRUDED FLEXOMER™ DFDA 9020 NT 7 POLYOLEFIN

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A2	80	ss	0 6	14	--- 262 ± 14	58.82 ± 3.64 59.68 ± 0.77
	85	ss	0 6	14	--- 278 ± 22	59.57 ± 1.24 59.71 ± 0.84
	90	ss	0 6	14	--- 271 ± 20	59.54 ± 0.73 59.46 ± 0.41
	95	ss	0 6	14	--- 296 ± 22	59.91 ± 1.15 59.51 ± 0.64
	100	ss	0 6	14	--- 289 ± 17	60.09 ± 0.84 60.83 ± 4.08
	105	ss	0 6	14	--- 283 ± 15	59.99 ± 1.31 60.04 ± 0.92
	80	pl	0 6	14	--- 281 ± 41	57.99 ± 1.83 57.30 ± 2.62
	85	pl	0 6	14	--- 302 ± 20	58.18 ± 0.89 57.77 ± 0.63
	90	pl	0 6	14	--- 291 ± 21	59.11 ± 0.69 58.42 ± 0.68
	95	pl	0 6	14	--- 354 ± 103	58.54 ± 0.80 57.79 ± 0.63

Table 15 - continued						
Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/Yr)	Valve Delivery (mg/actuation)
	100	pl	0 6	14	--- 319 ± 16	58.59 ± 1.09 58.58 ± 2.84
	105	pl	0 6	14	--- 319 ± 30	58.20 ± 0.74 57.99 ± 1.23

TABLE 16
COMPRESSION MOLDED FLEXOMER™ DFDA 9020 N7 POLYOLEFIN

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A3	80	pl	0 6	14	--- not measured	59.43 ± 0.70 58.82 ± 0.74
	85	pl	0 6	14	--- 240 ± 15	59.27 ± 0.78 58.76 ± 0.41
	90	pl	0 6	14	--- 230 ± 18	59.44 ± 2.03 58.67 ± 0.83
	95	pl	0 6	14	--- 236 ± 17	59.09 ± 0.73 58.95 ± 0.79
	100	pl	0 6	14	--- 243 ± 76	58.51 ± 2.49 58.06 ± 2.04
B2	105	pl	0 6	14	--- 304 ± 253	59.00 ± 1.27 58.63 ± 1.98
	80	ss	0 6	14	--- 221 ± 90	65.57 ± 1.14 66.66 ± 0.86
	85	ss	0 6	14	--- 338 ± 228	65.75 ± 0.80 66.67 ± 1.42
	90	ss	0 6	14	--- 471 ± 482	65.56 ± 1.30 66.74 ± 0.80
	95	ss	0 6	14	--- 424 ± 381	66.35 ± 2.19 67.03 ± 0.93

Table 16 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	100	ss	0 6	14	--- 564 ± 490	65.72 ± 0.67 66.40 ± 0.60
	105	ss	0 6	14	--- 671 ± 622	66.40 ± 1.32 66.43 ± 1.14
B2	80	pl	0 6	14	--- 174 ± 18	63.26 ± 0.48 63.41 ± 0.50
	85	pl	0 6	14	--- 186 ± 21	62.93 ± 0.86 63.80 ± 0.78
	90	pl	0 6	14	--- 179 ± 13	63.50 ± 0.97 64.24 ± 0.89
	95	pl	0 6	14	--- 175 ± 10	62.82 ± 1.71 64.58 ± 1.13
	100	pl	0 6	14	--- 174 ± 33	62.60 ± 2.83 63.43 ± 1.69
	105	pl	0 6	14	--- 168 ± 18	63.51 ± 1.47 66.57 ± 8.55

- 64 -

The results in TABLES 15 and 16 show that the extruded and compression molded diaphragms have valve delivery and leak rate especially suitable for use with a polar ionized drug (albuterol sulfate),
5 while the compression molded diaphragms used with the plastic valve stem are particularly suitable for use with a steroid formulation (beclomethasone dipropionate).

Diaphragms of the invention were prepared
10 from FLEXOMER™ DEFD 9042 NT polyolefin and tested with the formulations indicated in TABLES 17-19 below.

TABLE 17
COMPRESSION MOLDED FLEXOMER™ 9042 NT POLYOLEFIN

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A1	80	SS	0 3	14	--- 270 ± 20	61.59 ± 1.50 63.14 ± 0.88
	85	SS	0 6	14	--- 249 ± 22	60.77 ± 2.30 63.18 ± 1.04
	90	SS	0 6	14	--- 252 ± 19	58.94 ± 4.45 60.86 ± 2.81
	95	SS	0 6	14	--- 251 ± 21	59.81 ± 2.42 60.46 ± 2.22
	100	SS	0 6	14	--- 270 ± 33	44.61 ± 13.56 50.75 ± 5.58
	105	SS	0 6	14	--- 187 ± 25	58.16 ± 1.23 59.01 ± 0.82
	80	pl	0 6	14	--- 268 ± 22	61.14 ± 0.59 61.29 ± 0.66
	85	pl	0 6	14	--- 265 ± 14	59.96 ± 1.28 60.41 ± 0.88
	90	pl	0 6	14	--- 339 ± 141	57.35 ± 1.68 55.71 ± 5.71
	95	pl	0 6	14	--- 286 ± 30	54.95 ± 2.84 55.44 ± 3.48

TABLE 17 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/Yr)	Valve Delivery (mg/actuation)
	100	pl	0 6	14	--- 304 ± 24	55.37 ± 4.10 56.25 ± 3.33
	105	pl	0 6	14	--- 208 ± 31	57.83 ± 0.67 60.14 ± 2.62

TABLE 18
EXTRUDED FLEXOMER™ DEFD 9042 NT POLYOLEFIN

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A2	80	SS	0	14	---	61.21 ± 1.86
			6		289 ± 85	61.10 ± 1.26
	85	SS	0	14	---	60.89 ± 1.62
			6		281 ± 63	60.50 ± 3.44
	90	SS	0	14	---	61.18 ± 2.86
			6		294 ± 64	60.65 ± 1.09
	95	SS	0	14	---	58.47 ± 1.01
			6		252 ± 18	60.59 ± 1.20
	100	SS	0	14	---	59.40 ± 1.27
			6		265 ± 12	60.35 ± 1.16
	105	SS	0	14	---	59.94 ± 1.22
			6		437 ± 375	60.97 ± 0.69
	80	pl	0	14	---	57.99 ± 0.72
			6		246 ± 9	57.71 ± 0.52
	85	pl	0	14	---	58.12 ± 0.98
			6		262 ± 10	53.93 ± 15.53

TABLE 18 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	90	pl	0 6	14	--- 262 ± 16	57.88 ± 0.85 57.40 ± 1.79
	95	pl	0 6	14	--- 256 ± 14	58.15 ± 1.10 57.88 ± 1.44
	100	pl	0 6	14	--- 268 ± 26	57.06 ± 1.40 57.31 ± 0.79
	105	pl	0 6	14	--- 316 ± 94	56.21 ± 1.68 59.84 ± 6.31

TABLE 19
INJECTION MOLDED FLEXOMER™ DEFD 9042 NT POLYOLEFIN

Formulation	ID	Stem	Time (weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A2	84	SS	0 6	10	--- 282 ± 13	60.40 ± 1.70 67.20 ± 8.78
	88	SS	0 6	10	--- 282 ± 13	60.40 ± 1.28 75.56 ± 25.41
	94	SS	0 6	10	--- 282 ± 14	61.60 ± 2.07 66.63 ± 13.64
	99	SS	0 6	10	--- 297 ± 16	60.83 ± 2.18 62.80 ± 3.61
	84	pl	0 6	10	--- 272 ± 14	59.00 ± 1.82 61.30 ± 8.54
	88	pl	0 6	10	--- 286 ± 22	65.99 ± 12.41 60.32 ± 4.43
	94	pl	0 6	10	--- 284 ± 18	61.20 ± 3.64 60.28 ± 3.42
	99	pl	0 6	10	--- 291 ± 8	61.22 ± 4.87 59.40 ± 3.19

TABLE 19 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/Yr)	Valve Delivery (mg/actuation)
B2	84	ss	0 6	10	--- 198 ± 11	70.48 ± 10.53 69.54 ± 3.92
	88	ss	0 6	10	--- 202 ± 18	64.71 ± 1.23 71.80 ± 7.10
	94	ss	0 6	10	--- 199 ± 18	65.01 ± 2.66 86.26 ± 31.64
	99	ss	0 6	10	--- 208 ± 30	66.80 ± 5.98 80.90 ± 34.78
B2	84	pl	0 6	10	--- 207 ± 15	64.81 ± 3.57 63.90 ± 1.47
	88	pl	0 6	10	--- 200 ± 10	63.96 ± 4.78 64.46 ± 2.31
	94	pl	0 6	10	--- 207 ± 14	65.17 ± 4.19 69.00 ± 7.64
	99	pl	0 6	10	--- 219 ± 22	65.27 ± 3.27 78.26 ± 40.98

The results in TABLES 17-19 show that in this instance compression molded and extruded diaphragms generally perform better than the injection molded diaphragms with these formulations.

- 5 Diaphragms of the invention were prepared from polymer blends of the invention as set forth in TABLES 20-25 (parts and percentages are by weight) and tested with the formulations indicated in said TABLES.

TABLE 20
COMPRESSION MOLDED POLYMER BLEND. DFDA 1137 NT 7/GERS 1085 NT (25/75)

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A1	80	ss	0 6	10	---	55.70 ± 1.91
					271 ± 18	56.55 ± 0.62
	85	ss	0 6	10	---	54.38 ± 6.57
					261 ± 12	57.31 ± 0.88
	90	ss	0 6	10	---	56.08 ± 1.96
					264 ± 10	57.22 ± 0.96
	95	ss	0 6	10	---	56.00 ± 1.08
					264 ± 15	56.97 ± 1.09
	100	ss	0 6	10	---	55.54 ± 1.03
					266 ± 12	56.91 ± 0.84
	105	ss	0 6	10	---	56.45 ± 0.89
					278 ± 19	57.49 ± 0.62
	80	pl	0 6	10	---	54.29 ± 1.45
					259 ± 12	54.81 ± 0.41
	85	pl	0 6	10	---	54.93 ± 0.89
					271 ± 18	55.79 ± 0.71
	90	pl	0 6	10	---	55.63 ± 0.89
					264 ± 7	55.39 ± 0.60

TABLE 20 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	95	pl	0 6	10	--- 271 ± 13	55.43 ± 1.02 55.34 ± 1.32
	100	pl	0 6	10	--- 283 ± 24	55.56 ± 0.47 55.70 ± 0.88
	105	pl	0 6	10	--- 280 ± 17	55.75 ± 0.75 56.17 ± 1.06
B1	80	ss	0 6	10	--- 234 ± 12	60.45 ± 0.85 61.10 ± 0.80
	85	ss	0 6	10	--- 224 ± 16	59.99 ± 1.88 62.23 ± 0.92
	90	ss	0 6	10	--- 232 ± 17	60.23 ± 0.74 61.52 ± 0.54
	95	ss	0 6	10	--- 242 ± 28	60.27 ± 0.95 61.37 ± 0.58
	100	ss	0 6	10	--- 230 ± 17	60.77 ± 0.59 61.65 ± 0.62
	105	ss	0 6	10	--- 240 ± 17	60.56 ± 0.87 63.19 ± 3.70

TABLE 20 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/Yr)	Valve Delivery (mg/actuation)
	80	pl	0 6	10	--- 222 ± 22	59.08 ± 0.64 59.35 ± 0.46
	85	pl	0 6	10	--- 236 ± 22	58.83 ± 2.94 60.18 ± 0.87
	90	pl	0 6	10	--- 234 ± 20	59.55 ± 0.79 60.05 ± 1.17
	95	pl	0 6	10	--- 255 ± 24	59.14 ± 1.68 59.80 ± 2.01
	100	pl	0 6	10	--- 249 ± 20	59.91 ± 0.48 60.39 ± 1.38
	105	pl	0 6	10	--- 249 ± 16	59.32 ± 0.61 60.00 ± 0.37

TABLE 21
COMPRESSION MOLDED POLYMER BLEND. DFDA 1137 NT 7/GERS 1085 NT (50/50)

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A1	80	ss	0	10	---	57.35 ± 1.07
			6		267 ± 15	58.50 ± 0.54
	85	ss	0	10	---	56.97 ± 0.64
			6		273 ± 14	57.92 ± 0.64
	90	ss	0	10	---	56.87 ± 0.87
			6		279 ± 24	57.99 ± 0.74
	95	ss	0	10	---	57.65 ± 1.16
			6		267 ± 10	58.46 ± 0.89
	100	ss	0	10	---	57.17 ± 1.06
			6		265 ± 16	57.98 ± 0.85
	105	ss	0	10	---	57.83 ± 1.10
			6		266 ± 11	58.77 ± 0.88
	80	pl	0	10	---	56.73 ± 0.66
			6		284 ± 17	55.55 ± 3.81
	85	pl	0	10	---	56.13 ± 1.85
			6		282 ± 23	56.23 ± 0.77
	90	pl	0	10	---	56.87 ± 0.59
			6		267 ± 9	56.41 ± 0.99

TABLE 21 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	95	pl	0 6	10	--- 285 ± 29	56.69 ± 0.73 57.21 ± 0.38
	100	pl	0 6	10	--- 269 ± 8	55.28 ± 3.52 56.98 ± 0.55
	105	pl	0 6	10	--- 271 ± 12	57.15 ± 0.41 57.06 ± 0.62
B1	80	ss	0 6	10	--- 206 ± 9	61.83 ± 0.93 63.37 ± 0.87
	85	ss	0 6	10	--- 206 ± 17	60.98 ± 0.78 62.90 ± 0.99
	90	ss	0 6	10	--- 196 ± 11	61.80 ± 0.85 63.12 ± 0.94
	95	ss	0 6	10	--- 205 ± 11	61.94 ± 1.11 63.26 ± 0.86
	100	ss	0 6	10	--- 201 ± 13	61.94 ± 0.95 62.99 ± 0.97
	105	ss	0 6	10	--- 192 ± 12	62.61 ± 0.96 63.70 ± 0.78

TABLE 21 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	80	pl	0 6	10	--- 210 ± 19	60.39 ± 0.60 61.08 ± 0.71
	85	pl	0 6	10	--- 211 ± 11	59.80 ± 0.38 61.44 ± 1.31
	90	pl	0 6	10	--- 202 ± 10	61.52 ± 0.58 61.89 ± 0.63
	95	pl	0 6	10	--- 193 ± 8	55.62 ± 17.44 61.96 ± 0.94
	100	pl	0 6	10	--- 202 ± 13	61.30 ± 0.52 62.18 ± 0.56
	105	pl	0 6	10	--- 203 ± 15	61.53 ± 0.86 61.68 ± 0.75

TABLE 22
COMPRESSION MOLDED POLYMER BLEND. DFDA 1137 NT 7/GERS 1085 NT (75/25)

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A1	80	SS	0	10	---	57.92 \pm 1.25
			6		374 \pm 24	58.18 \pm 0.84
	85	SS	0	10	---	58.31 \pm 0.90
			6		385 \pm 27	58.85 \pm 0.80
	90	SS	0	10	---	58.01 \pm 0.58
			6		332 \pm 16	58.85 \pm 0.80
	95	SS	0	10	---	57.93 \pm 0.84
			6		314 \pm 28	58.86 \pm 0.77
	100	SS	0	10	---	57.23 \pm 1.01
			6		294 \pm 16	58.20 \pm 0.94
	105	SS	0	10	---	58.07 \pm 1.13
			6		324 \pm 19	58.61 \pm 1.07
	80	pl	0	10	---	57.07 \pm 1.02
			6		392 \pm 20	57.31 \pm 0.62
	85	pl	0	10	---	57.39 \pm 0.39
			6		380 \pm 41	57.83 \pm 0.53
	90	pl	0	10	---	57.14 \pm 0.51
			6		340 \pm 27	57.45 \pm 0.81

TABLE 22 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/Yr)	Valve Delivery (mg/actuation)
	95	pl	0 6	10	--- 299 ± 16	57.54 ± 0.50 57.44 ± 0.57
	100	pl	0 6	10	--- 309 ± 13	56.95 ± 0.71 57.38 ± 2.62
	105	pl	0 6	10	--- 331 ± 29	56.13 ± 1.71 56.78 ± 0.80
B1	80	ss	0 6	10	--- 205 ± 13	61.92 ± 0.77 63.21 ± 0.61
	85	ss	0 6	10	--- 201 ± 6	61.81 ± 0.52 63.52 ± 0.57
	90	ss	0 6	10	--- 201 ± 11	61.80 ± 1.23 63.63 ± 1.68
	95	ss	0 6	10	--- 201 ± 15	61.86 ± 0.86 63.32 ± 0.98
	100	ss	0 6	10	--- 209 ± 23	62.16 ± 0.94 63.64 ± 0.97
	105	ss	0 6	10	--- 204 ± 11	62.46 ± 0.83 63.39 ± 1.11

TABLE 22 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	80	pl	0 6	10	--- 199 ± 11	60.75 ± 0.62 61.62 ± 0.64
	85	pl	0 6	10	--- 212 ± 16	60.93 ± 0.50 62.08 ± 0.72
	90	pl	0 6	10	--- 205 ± 14	60.44 ± 1.84 62.48 ± 1.21
	95	pl	0 6	10	--- 205 ± 7	61.06 ± 0.47 62.12 ± 0.95
	100	pl	0 6	10	--- 210 ± 27	60.49 ± 0.68 61.41 ± 0.67
	105	pl	0 6	10	--- 201 ± 13	60.54 ± 2.61 61.96 ± 0.74

TABLE 23
COMPRESSION MOLDED POLYMER BLEND. DFDA 1137 NT 7/GERS 1085 NT/TALC (23.2/69.8/7.0)

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A2	80	ss	0 6	10	--- 296 ± 37	59.26 ± 1.00 59.82 ± 1.06
	85	ss	0 6	10	--- 265 ± 31	59.19 ± 0.85 60.39 ± 0.83
	90	ss	0 6	10	--- 278 ± 34	60.44 ± 1.07 62.03 ± 0.70
	95	ss	0 6	10	--- 313 ± 43	59.71 ± 1.90 61.78 ± 0.57
	100	ss	0 6	10	--- 303 ± 40	59.61 ± 0.84 61.31 ± 0.84
	105	ss	0 6	10	--- 311 ± 53	59.98 ± 1.21 61.49 ± 1.06
	80	pl	0 6	10	--- 300 ± 48	57.71 ± 0.70 57.54 ± 0.63
	85	pl	0 6	10	--- 264 ± 29	57.73 ± 0.54 57.56 ± 0.33
	90	pl	0 6	10	--- 287 ± 33	58.04 ± 0.78 58.46 ± 0.64

TABLE 23 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	95	pl	0 6	10	--- 282 ± 22	58.24 ± 0.70 58.79 ± 0.59
	100	pl	0 6	10	--- 310 ± 43	57.80 ± 0.44 59.33 ± 1.45
	105	pl	0 6	10	--- 366 ± 39	58.30 ± 0.61 59.16 ± 0.44
B2	80	ss	0 6	10	--- 194 ± 6	61.80 ± 1.00 not measured
	85	ss	0 6	10	--- 185 ± 16	61.94 ± 0.98 64.04 ± 0.69
	90	ss	0 6	10	--- 206 ± 28	61.40 ± 2.70 65.21 ± 0.88
	95	ss	0 6	10	--- 196 ± 15	62.82 ± 1.03 65.31 ± 0.81
	100	ss	0 6	10	--- 218 ± 35	60.04 ± 6.25 65.37 ± 0.67
	105	ss	0 6	10	--- 215 ± 36	63.57 ± 1.54 65.14 ± 0.77

TABLE 23 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	80	pl	0 6	10	--- 221 ± 41	60.74 ± 0.73 61.69 ± 0.65
	85	pl	0 6	10	--- 188 ± 7	60.69 ± 0.79 61.99 ± 0.72
	90	pl	0 6	10	--- 199 ± 13	61.33 ± 0.88 62.34 ± 0.53
	95	pl	0 6	10	--- 212 ± 18	61.13 ± 0.72 63.36 ± 1.23
	100	pl	0 6	10	--- 210 ± 24	60.71 ± 1.08 64.28 ± 2.53
	105	pl	0 6	10	--- 205 ± 33	61.28 ± 0.44 64.10 ± 1.27

TABLE 24
COMPRESSION MOLDED POLYMER BLEND. DFDA 1137 NT 7/GERS 1085 NT/ TALC (46.5/46.5/7.0)

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A2	80	ss	0	10	---	57.80 \pm 3.05
			6		241 \pm 26	61.25 \pm 0.81
	85	ss	0	10	---	60.00 \pm 0.91
			6		229 \pm 15	61.72 \pm 0.94
	90	ss	0	10	---	60.37 \pm 0.90
			6		266 \pm 34	62.18 \pm 0.74
	95	ss	0	10	---	59.91 \pm 0.95
			6		266 \pm 26	61.84 \pm 0.92
	100	ss	0	10	---	59.70 \pm 1.15
			3		231 \pm 30	61.31 \pm 1.01
	105	ss	0	10	---	60.59 \pm 1.22
			6		293 \pm 38	61.76 \pm 0.72
	80	pl	0	10	---	58.27 \pm 0.56
			6		248 \pm 24	57.59 \pm 2.34
	85	pl	0	10	---	58.17 \pm 1.13
			6		238 \pm 21	59.03 \pm 0.37
	90	pl	0	10	---	57.39 \pm 2.30
			6		244 \pm 19	57.94 \pm 2.34

TABLE 24 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	95	pl	0 6	10	--- 280 ± 40	58.69 ± 0.61 59.20 ± 0.85
	100	pl	0 6	10	--- 297 ± 30	58.53 ± 0.52 59.55 ± 1.40
	105	pl	0 6	10	--- 280 ± 30	58.88 ± 0.30 60.89 ± 2.31
B2	80	ss	0 6	10	--- 186 ± 20	64.01 ± 1.29 65.56 ± 0.70
	85	ss	0 6	10	--- 191 ± 9	63.40 ± 0.71 65.8 ± 0.92
	90	ss	0 6	10	--- 200 ± 16	63.40 ± 1.26 65.74 ± 1.21
	95	ss	0 6	10	--- 197 ± 9	63.07 ± 0.74 65.83 ± 0.74
	100	ss	0 6	10	--- 194 ± 9	63.02 ± 1.44 65.51 ± 1.62
	105	ss	0 6	10	--- 185 ± 10	63.98 ± 0.64 65.71 ± 0.98

TABLE 24 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	80	pl	0 6	10	--- 200 ± 19	61.25 ± 0.50 62.19 ± 0.42
	85	pl	0 6	10	--- 197 ± 14	61.69 ± 0.62 62.58 ± 1.28
	90	pl	0 6	10	--- 200 ± 12	61.43 ± 1.51 62.77 ± 0.88
	95	pl	0 6	10	--- 208 ± 14	61.50 ± 0.57 63.75 ± 0.91
	100	pl	0 6	10	--- 203 ± 10	62.26 ± 0.54 64.25 ± 2.12
	105	pl	0 6	10	--- 188 ± 13	61.94 ± 0.58 63.39 ± 0.64

TABLE 25
COMPRESSION MOLDED POLYMER BLEND. DFDA 1137 NT 7/GERS 1085 NT/TALC (69.8/23.2/7.0)

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A2	80	ss	0 6	10	--- 330 ± 53	60.31 ± 0.91 62.18 ± 0.90
	85	ss	0 6	10	--- 422 ± 197	60.53 ± 1.09 62.01 ± 0.70
	90	ss	0 6	10	--- 302 ± 59	59.66 ± 1.41 62.05 ± 0.74
	95	ss	0 6	10	--- 333 ± 74	60.06 ± 1.36 62.10 ± 0.77
	100	ss	0 6	10	--- 331 ± 42	61.05 ± 1.03 61.70 ± 0.83
	105	ss	0 6	10	--- 297 ± 41	60.86 ± 0.93 61.50 ± 1.01
	80	pl	0 6	10	--- 288 ± 41	58.44 ± 0.54 58.22 ± 1.62
	85	pl	0 6	10	--- 303 ± 30	58.73 ± 0.44 59.01 ± 0.56
	90	pl	0 6	10	--- 275 ± 29	58.79 ± 0.66 59.52 ± 0.61

TABLE 25 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	95	pl	0 6	10	--- 302 ± 59	58.87 ± 1.21 60.48 ± 1.39
	100	pl	0 6	10	--- 306 ± 33	59.35 ± 0.66 61.10 ± 1.59
	105	pl	0 6	10	--- 302 ± 38	59.24 ± 0.59 58.71 ± 3.32
B2	80	ss	0 6	10	--- 230 ± 69	64.24 ± 0.51 65.83 ± 0.56
	85	ss	0 6	10	--- 231 ± 145	63.78 ± 1.10 65.94 ± 1.09
	90	ss	0 6	10	--- 201 ± 17	64.50 ± 1.30 66.09 ± 0.66
	95	ss	0 6	10	--- 204 ± 19	62.51 ± 1.58 66.05 ± 1.10
	100	ss	0 6	10	--- 202 ± 27	64.14 ± 0.81 65.86 ± 0.92
	105	ss	0 6	10	--- 219 ± 70	64.41 ± 0.92 66.38 ± 0.96

TABLE 25- continued						
Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/Yr)	Valve Delivery (mg/actuation)
	80	p1	0 6	10	--- 199 ± 10	62.09 ± 0.49 62.50 ± 0.59
	85	p1	0 6	10	--- 199 ± 16	61.77 ± 1.82 64.04 ± 1.66
	90	p1	0 6	10	--- 202 ± 17	62.47 ± 0.66 63.89 ± 1.54
	95	p1	0 6	10	--- 198 ± 13	62.50 ± 0.52 63.87 ± 1.27
	100	p1	0 6	10	--- 206 ± 18	62.67 ± 0.64 66.47 ± 4.74
	105	p1	0 6	10	--- 194 ± 12	62.35 ± 0.49 63.83 ± 0.92

- 90 -

The results in TABLES 20-25 show that the indicated blends are suitable seal materials for use with metered dose inhalers containing the indicated formulations. Moreover, the data indicate that blends 5 in all proportions would be suitable.

Diaphragms of the invention were prepared from ATTANE™ 4602 polyolefin and ATTANE™ 4701 polyolefin and tested with the formulations indicated in TABLE 26 and TABLE 27 below, respectively:

TABLE 26
COMPRESSION MOLDED ATTANE[™] 4602 POLYOLEFIN

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A3	80	SS	0	10	---	62.21 ± 0.76
			6		1442 ± 595	61.43 ± 1.65
	85	SS	0	10	---	62.37 ± 1.64
			6		1611 ± 499	61.31 ± 1.07
	90	SS	0	10	---	62.17 ± 0.65
			6		1917 ± 1245	61.45 ± 1.90
	95	SS	0	10	---	61.71 ± 0.47
			6		1410 ± 720	60.41 ± 4.32
	100	SS	0	10	---	61.46 ± 1.04
			6		1177 ± 644	54.14 ± 16.75
	105	SS	0	10	---	61.78 ± 1.17
			6		1824 ± 2007	61.58 ± 0.96
	80	pl	0	10	---	59.41 ± 0.34
			6		285 ± 23	58.38 ± 0.58
	85	pl	0	10	---	58.74 ± 1.70
			6		390 ± 216	56.81 ± 5.49

TABLE 26 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	90	pl	0 6	10	--- 316 ± 46	59.42 ± 0.62 58.40 ± 1.08
	95	pl	0 6	10	--- 440 ± 430	59.59 ± 0.62 56.25 ± 4.51
	100	pl	0 6	10	--- 328 ± 91	59.89 ± 0.64 59.84 ± 1.74
	105	pl	0 6	10	--- 419 ± 218	59.38 ± 1.03 60.04 ± 2.83
B2	80	ss	0 6	10	--- 802 ± 1034	66.53 ± 0.92 67.86 ± 0.81
	85	ss	0 6	10	--- 812 ± 425	66.14 ± 0.55 66.70 ± 0.72
	90	ss	0 6	10	--- 812 ± 644	66.18 ± 1.18 66.61 ± 0.85
	95	ss	0 6	10	--- 925 ± 712	65.97 ± 1.11 66.76 ± 0.80
	100	ss	0 6	10	--- 1067 ± 1137	66.02 ± 0.98 66.36 ± 1.03

TABLE 26 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	105	ss	0 6	10	--- 1169 ± 1462	66.29 ± 0.88 66.39 ± 1.96
	80	pl	0 6	10	--- 163 ± 17	63.92 ± 0.40 63.64 ± 0.95
	85	pl	0 6	10	--- 187 ± 31	63.72 ± 0.95 63.93 ± 0.70
	90	pl	0 6	10	--- 189 ± 42	64.26 ± 3.81 64.36 ± 0.82
	95	pl	0 6	10	--- 166 ± 13	63.57 ± 1.13 64.99 ± 3.07
	100	pl	0 6	10	--- 198 ± 38	63.55 ± 1.47 65.23 ± 2.72
	105	pl	0 6	10	--- 2334 ± 3940	65.46 ± 2.42 74.03 ± 33.09

TABLE 27 - COMPRESSION MOLDED ATTANE™ 4701 POLYOLEFIN

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A3	80	ss	0 6	10	--- 2377 ± 394	61.73 ± 0.81 60.04 ± 3.46
	85	ss	0 6	10	--- 2263 ± 1534	62.27 ± 0.88 61.84 ± 0.71
	90	ss	0 6	10	--- 1817 ± 793	62.37 ± 0.69 61.98 ± 0.46
	95	ss	0 6	10	--- 2447 ± 2861	61.81 ± 0.63 61.09 ± 1.57
	100	ss	0 6	10	--- 2441 ± 1081	61.79 ± 0.79 61.35 ± 0.94
	105	ss	0 6	10	--- 1480 ± 867	61.21 ± 0.85 60.67 ± 0.92
	80	pl	0 6	10	--- 356 ± 71	59.51 ± 0.85 58.45 ± 0.84
	85	pl	0 6	10	--- 294 ± 21	59.43 ± 1.31 57.03 ± 2.39
	90	pl	0 6	10	--- 322 ± 59	59.62 ± 0.65 58.96 ± 0.62
	95	pl	0 6	10	--- 297 ± 26	59.50 ± 0.69 58.77 ± 1.03

TABLE 27 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	100	pl	0 6	10	--- 326 ± 33	57.92 ± 2.91 58.49 ± 0.99
	105	pl	0 6	10	--- 1093 ± 1193	57.30 ± 5.32 58.23 ± 0.71
B2	80	ss	0 6	10	--- 617 ± 382	66.58 ± 1.01 67.42 ± 1.08
	85	ss	0 6	10	--- 745 ± 610	67.25 ± 1.56 67.40 ± 0.72
	90	ss	0 6	10	--- 716 ± 489	66.75 ± 1.01 67.44 ± 1.01
	95	ss	0 6	10	--- 797 ± 602	66.86 ± 0.74 67.05 ± 0.76
	100	ss	0 6	10	--- 1145 ± 1080	66.36 ± 0.66 67.06 ± 0.41
	105	ss	0 6	10	--- 1020 ± 731	66.18 ± 0.98 66.33 ± 0.90
	80	pl	0 6	10	--- 176 ± 20	64.11 ± 0.44 63.87 ± 0.74

TABLE 27 - continued

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
	85	pl	0 6	10	--- 175 ± 17	63.45 ± 1.06 63.97 ± 0.79
	90	pl	0 6	10	--- 177 ± 16	64.14 ± 0.47 63.40 ± 3.13
	95	pl	0 6	10	--- 200 ± 68	63.17 ± 2.12 64.89 ± 1.22
	100	pl	0 6	10	--- 197 ± 11	63.96 ± 0.82 64.09 ± 0.78
	105	pl	0 6	10	--- 254 ± 174	63.46 ± 0.58 64.50 ± 1.25

- 97 -

The results in TABLES 26 and 27 show that diaphragms of these materials are suitable but perform notably better with the indicated albuterol sulfate and beclomethasone dipropionate formulations when used with
5 a plastic valve stem.

For comparative purposes, diaphragms were prepared from "Buna" rubber and from butyl rubber, both materials being commonly used in commercially available metered dose inhalers. These diaphragms were tested
10 with formulations as indicated in TABLES 28 and 29
below:

TABLE 28 - BUNA RUBBER

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/Yr)	Valve Delivery (mg/actuation)
A5	83	SS	0	20/12	---	50.56 ± 1.70
			4		386 ± 20	51.11 ± 1.33
			12		377 ± 14	53.82 ± 1.77
	88	SS	0	20/12	---	52.81 ± 1.64
			4		347 ± 49	52.97 ± 1.33
			12		392 ± 13	54.19 ± 2.70
	93	SS	0	20/12	---	53.05 ± 1.42
			4		345 ± 12	51.88 ± 3.76
			12		386 ± 13	54.14 ± 1.79
	98	SS	0	20/12	---	53.88 ± 1.80
			4		345 ± 16	53.78 ± 1.02
			12		388 ± 19	54.05 ± 1.14
	83	pl	0	20/12	---	50.62 ± 0.71
			4		312 ± 18	49.00 ± 1.18
			12		395 ± 160	51.02 ± 0.71
	88	pl	0	20/12	---	53.32 ± 1.80
			4		335 ± 12	52.53 ± 2.37
			12		380 ± 13	53.71 ± 0.79
	93	pl	0	20/12	---	51.22 ± 0.75
			4		324 ± 19	49.94 ± 1.36
			12		378 ± 22	51.00 ± 0.45
	98	pl	0	20/12	---	51.27 ± 0.60
			4		322 ± 12	50.57 ± 0.62
			12		368 ± 13	51.13 ± 0.63

TABLE 29 - BUTYL RUBBER

Formulation	ID	Stem	Time (Weeks)	N	Leak Rate (mg/yr)	Valve Delivery (mg/actuation)
A5	83	ss	0	20/12	---	58.86 ± 2.59
			4		174 ± 24	57.98 ± 2.04
			12		216 ± 16	58.13 ± 3.15
	88	ss	0	20/12	---	57.86 ± 2.49
			4		152 ± 9	58.02 ± 1.27
			12		197 ± 10	58.39 ± 3.32
	93	ss	0	20/12	---	59.12 ± 2.19
			4		151 ± 8	58.72 ± 3.35
			12		195 ± 9	58.92 ± 3.46
	98	ss	0	20/12	---	58.74 ± 2.54
			4		168 ± 28	58.02 ± 2.14
			12		208 ± 30	60.59 ± 4.11
	83	pl	0	20/12	---	55.92 ± 0.59
			4		159 ± 12	54.45 ± 1.73
			12		247 ± 160	54.62 ± 1.04
	88	pl	0	20/12	---	56.31 ± 0.28
			4		169 ± 25	54.50 ± 3.10
			12		218 ± 22	54.37 ± 2.59
	93	pl	0	20/12	---	56.20 ± 0.73
			4		161 ± 14	54.32 ± 1.58
			12		211 ± 15	55.04 ± 0.78
	98	pl	0	20/12	---	56.67 ± 1.11
			4		156 ± 11	55.16 ± 0.43
			12		204 ± 11	55.24 ± 0.78

- 100 -

The results in TABLES 28 and 29 show that, when used with the indicated formulations, "Buna" diaphragms generally exhibit leak rates higher than 300 mg/yr with generally acceptable valve delivery variability. The results also show that the butyl rubber diaphragms exhibit acceptable leak rates when used with the indicated formulations but valve delivery variability is not acceptable.

Diaphragms of the invention were prepared from the materials set forth in TABLES 30 and 31 and tested with the indicated formulations. In said TABLES, Valve "A" indicates that the valve used was a valve with a stainless steel valve stem, substantially as described herein and illustrated in the Drawing.

Valve "B" indicates that the valve used was a 50 μ L SPRAYMISER™ aerosol valve (Neotechnic Engineering Ltd.).

TABLE 30 - DIAPHRAGM PERFORMANCE WITH HFC-227

Formulation	Diaphragm Material	Valve	Time (Weeks)	N = 10 Leak Rate (mg/yr) \pm SD	N = 5 Valve Delivery (mg/actuation) \pm SD
P	GERS 1085 NT	A	0 3	--- 13 \pm 6	67.78 \pm 0.51 65.22 \pm 1.13
		B	0 3	--- 8 \pm 8	65.84 \pm 1.14 66.08 \pm 0.70
	DFDA 1137 NT7 = 50 GERS 1085 NT 50	A	0 3	--- 12 \pm 6	66.40 \pm 4.30 68.34 \pm 0.86
		B	0 3	--- 3 \pm 4	68.20 \pm 1.02 68.68 \pm 0.64
	DFDA 1137 NT7 46.5 GERS 1085 NT = 46.5 Talc 7.0	A	0 3	--- 15 \pm 6	69.08 \pm 1.32 67.58 \pm 1.70
		B	0 3	--- 6 \pm 5	69.34 \pm 0.89 68.94 \pm 0.36
	Attane™ 4602	A	0 3	--- 11 \pm 3	70.72 \pm 0.52 67.86 \pm 1.99
		B	0 3	--- 32 \pm 59	70.70 \pm 0.56 69.46 \pm 3.16
	Attane™ 4701	A	0 3	--- 12 \pm 8	70.84 \pm 1.23 69.78 \pm 1.57
		B	0 3	--- 5 \pm 6	70.14 \pm 2.10 69.76 \pm 1.42

TABLE 31
Diaphragm Performance With HFC-227 Formulations

Formulation	Diaphragm	Valve	Time (Weeks)	N = 10 Leak Rate (mg/yr) +SD	N = 5 Valve Delivery (mg/actuation) +SD
A7	GERS 1085 NT	A	0 *	---	68.27 ± 6.23
		B	0 *	47 ± 9	40.60 ± 28.88
			0 *	---	75.42 ± 1.64
			0 *	41 ± 9	75.60 ± 0.91
	DFDA 1137 NT7 = 50	A	0 *	---	75.88 ± 3.74
	GERS 1085 NT 50		0 *	66 ± 56	21.22 ± 7.61
		B	0 *	---	78.30 ± 1.13
			0 *	37 ± 9	77.92 ± 0.25
	DFDA 1137 NT7 46.5	A	0 *	---	74.84 ± 1.62
	GERS 1085 NT = 46.5		0 *	50 ± 14	76.70 ± 2.23
	Talc 7.0				
		B	0 *	---	79.70 ± 4.78
			0 *	37 ± 9	78.33 ± 0.71
	Attane™ 4602	A	0 *	---	79.10 ± 4.46
			0 *	7047 ± 4844	80.00 ± 1.95
		B	0 *	---	78.60 ± 0.83
			0 *	60 ± 55	58.82 ± 28.9
	Attane™ 4701	A	0 *	---	77.44 ± 2.67
			0 *	43 ± 8	77.48 ± 12.02
		B	0 *	---	76.30 ± 3.50
			0 *	30 ± 15	66.60 ± 13.02

* leak rate measured over one week during the fourth week of storage at 30°C. The valve delivery measurements, however, were made after 3 weeks of storage at 30°C.

- 103 -

The results in TABLES 30 and 31 indicate that these diaphragms of the invention function as seal materials for use in the dynamic pressure seal of a metered dose inhaler containing a formulation that
5 comprises HFC-227. Furthermore, these data demonstrate the dramatic difference in valve delivery variability depending on the presence of a small amount of ethanol as a formulation component and the nature of the drug substance. The difference between valve A and valve B
10 is especially clear in TABLE 31 where Valve A affords unsatisfactory valve delivery variability while valve B exhibits very low variability. Within a valve type, for example valve B, the material from which the diaphragm is constructed also has an important effect,
15 which is illustrated by the results for GERS 1085 NT and the several blends on one hand, and ATTANE™ 4602 and ATTANE™ on the other hand.

- 104 -

The Claimed Invention Is:

1. A device for delivering an aerosol, comprising: a valve stem, a diaphragm having walls
5 defining a diaphragm aperture, and a casing member having walls defining a casing aperture, wherein the valve stem passes through the diaphragm aperture and the casing aperture and is in slidable sealing engagement with the diaphragm aperture, and wherein the
10 diaphragm is in sealing engagement with the casing member, the diaphragm material comprising: a thermoplastic elastomer comprising a copolymer of about 80 to about 95 mole percent ethylene and a total of about 5 to about 20 mole percent of one or more
15 comonomers selected from the group consisting of 1-butene, 1-hexene, and 1-octene.

2. A device according to Claim 1, wherein the sole comonomer is 1-butene.
20

3. A device according to Claim 1, wherein the sole comonomer is 1-hexene.

4. A device according to Claim 1, wherein
25 the sole comonomer is 1-octene.

5. A device according to Claim 1, wherein the thermoplastic elastomer comprises a copolymer of about 91 mole percent ethylene and about 9 mole percent
30 1-butene.

6. A device according to Claim 1, wherein the thermoplastic elastomer comprises a copolymer of about 88 mole percent ethylene and about 12 mole
35 percent 1-butene.

7. A device according to Claim 1, wherein the thermoplastic elastomer comprises a copolymer of about 80 mole percent ethylene and about 20 mole percent 1-butene.

5

8. A device according to Claim 1, wherein the thermoplastic elastomer comprises a copolymer of about 90 mole percent ethylene and about 10 mole percent 1-butene.

10

9. A device according to Claim 1, wherein the thermoplastic elastomer comprises a copolymer of about 92 mole percent ethylene and about 8 mole percent 1-butene.

15

10. A device according to Claim 1, wherein the thermoplastic elastomer comprises a copolymer of about 90 mole percent ethylene and about 10 mole percent 1-octene.

20

11. A device according to Claim 1, wherein the thermoplastic elastomer comprises a copolymer of about 92 mole percent ethylene and about 8 percent 1-octene.

25

12. A device according to Claim 1, wherein the thermoplastic elastomer comprises a copolymer of about 95 mole percent ethylene, about 1 mole percent 1-butene, and about 4 mole percent 1-hexene.

30

13. A device according to Claim 1, wherein the thermoplastic elastomer comprises a copolymer of about 94 mole percent ethylene, about 1 mole percent 1-butene, and about 5 mole percent 1-octene.

35

- 106 -

14. A device according to Claim 1, wherein the thermoplastic elastomer is a thermoplastic polymer blend comprising at least two thermoplastic copolymers, each comprising a copolymer of about 80 to about 95
5 mole percent ethylene and a total of about 5 to about 20 mole percent of one or more comonomers selected from the group consisting of 1-butene, 1-hexene, and 1-octene.

10 15. A device according to Claim 14, wherein the sole comonomer in each of the copolymers is 1-butene.

16. A device according to Claim 14,
15 wherein the thermoplastic polymer blend comprises (i) a copolymer of about 91 mole percent ethylene and about 9 mole percent 1-butene, and (ii) a copolymer of about 80 mole percent ethylene and about 20 mole percent 1-butene.

20 17. A device according to Claim 16, wherein the thermoplastic polymer blend comprises one part by weight of component (i) and about 0.25 to about 4 parts by weight of component (ii).

25 18. A device according to Claim 1, further comprising: a tank seal having walls defining a tank seal aperture, and a metering tank of a predetermined volume and having an inlet end, an inlet aperture, and
30 an outlet end, wherein the outlet end is in sealing engagement with the diaphragm, the valve stem passes through the inlet aperture and the tank seal aperture and is in slidable engagement with the tank seal aperture, and the tank seal is in sealing engagement
35 with the inlet end of the metering tank, and wherein the valve stem is movable between an extended closed position, in which the inlet end of the metering tank is open and the outlet end is closed, and a compressed

open position in which the inlet end of the metering tank is substantially sealed and the outlet end is open to the ambient atmosphere.

5 19. A device according to Claim 1, wherein the casing member defines a formulation chamber.

 20. A device according to Claim 19,
 wherein the formulation chamber contains an aerosol
10 formulation comprising 1,1,1,2-tetrafluoroethane,
 1,1,1,2,3,3,3-heptafluoropropane, or a mixture thereof,
 in an amount effective to function as a propellant.

 21. A device according to Claim 20,
15 wherein the formulation is a pharmaceutical formulation
 comprising 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-
 heptafluoropropane, or a mixture thereof, in an amount
 effective to function as an aerosol propellant, and a
 drug in an amount sufficient to provide a predetermined
20 number of therapeutically effective doses for
 inhalation.

 22. A device according to Claim 21,
 wherein the drug is a bronchodilator or a steroid.
25

 23. A device according to Claim 21,
 wherein the drug is albuterol sulfate.

 24. A device according to Claim 21,
30 wherein the drug is beclomethasone dipropionate.

 25. A device according to Claim 21,
 wherein the drug is pirbuterol acetate.

35 26. A device according to Claim 20,
 wherein the formulation further comprises ethanol.

- 108 -

27. A device according to Claim 26,
wherein the formulation further comprises oleic acid.

28. A thermoplastic elastomeric sealing
5 member for minimizing and/or preventing escape of
formulation components from a device for delivering an
aerosol, wherein the sealing member comprises a
thermoplastic elastomer comprising a copolymer of about
80 to about 95 mole percent ethylene and a total of
10 about 5 to about 20 mole percent of one or more
comonomers selected from the group consisting of
1-butene, 1-hexene, and 1-octene.

29. A sealing member according to Claim
15 28, wherein the elastomer comprises about 91 mole
percent ethylene and about 9 mole percent 1-butene,
wherein the respective monomer units are substantially
randomly distributed in the copolymer.

20 30. A sealing member according to Claim
28, wherein the elastomer comprises: a copolymer of
about 88 mole percent ethylene and about 12 mole
percent 1-butene.

25 31. A sealing member according to Claim
28, wherein the sole comonomer is 1-butene.

32. A sealing member according to Claim
28, wherein the sole comonomer is 1-hexene.

30 33. A sealing member according to Claim
28, wherein the sole comonomer is 1-octene.

34. A sealing member according to Claim
35 28, wherein the thermoplastic elastomer comprises a
copolymer of about 80 mole percent ethylene and about
20 mole percent 1-butene.

35. A sealing member according to Claim 28, wherein the thermoplastic elastomer comprises a copolymer of about 90 mole percent ethylene and about 10 mole percent 1-butene.

5

36. A sealing member according to Claim 28, wherein the thermoplastic elastomer comprises a copolymer of about 92 mole percent ethylene and about 8 mole percent 1-butene.

10

37. A sealing member according to Claim 28, wherein the thermoplastic elastomer comprises a copolymer of about 90 mole percent ethylene and about 10 mole percent 1-octene.

15

38. A sealing member according to Claim 28, wherein the thermoplastic elastomer comprises a copolymer of about 92 mole percent ethylene and about 8 percent 1-octene.

20

39. A sealing member according to Claim 28, wherein the thermoplastic elastomer comprises a copolymer of about 95 mole percent ethylene, about 1 mole percent 1-butene, and about 4 mole percent 1-hexene.

25

40. A sealing member according to Claim 28, wherein the thermoplastic elastomer comprises a copolymer of about 94 mole percent ethylene, about 1 mole percent 1-butene, and about 5 mole percent 1-octene.

30

41. A sealing member according to Claim 28, wherein the thermoplastic elastomer is a thermoplastic polymer blend comprising at least two thermoplastic copolymers, each comprising a copolymer of about 80 to about 95 mole percent ethylene and a total of about 5 to about 20 mole percent of one or

35

- 110 -

more comonomers selected from the group consisting of 1-butene, 1-hexene, and 1-octene.

42. A sealing member according to Claim
5 41, wherein the sole comonomer in each of the copolymers is 1-butene.

43. A sealing member according to Claim
41, wherein the thermoplastic polymer blend comprises
10 (i) a copolymer of about 91 mole percent ethylene and about 9 mole percent 1-butene and (ii) a copolymer of about 80 mole percent ethylene and about 20 mole percent 1-butene.

15 44. A sealing member according to Claim 43, wherein the thermoplastic polymer blend comprises one part by weight of component (i) and about 0.25 to about 4 parts by weight of component (ii).

20 45. A sealing member according to Claim 28 further comprising talc.

46. A sealing member according to Claim
28, in the form of a diaphragm

25 47. A sealing member according to Claim 28, in the form of an O-ring.

48. A sealing member according to Claim
30 28, in the form of a gasket.

49. A sealing member according to Claim
28, in the form of a tank seal.

35 50. A thermoplastic polymer blend comprising at least two thermoplastic copolymers, each comprising a copolymer of about 80 to about 95 mole percent ethylene and a total of about 5 to about 20

- 111 -

mole percent of one or more comonomers selected from the group consisting of 1-butene, 1-hexene, and 1-octene.

5 51. A polymer blend according to Claim 50, wherein the sole comonomer in each copolymer is 1-butene.

10 52. A polymer blend according to Claim 50, comprising (i) a copolymer of about 91 mole percent ethylene and about 9 mole percent 1-butene and (ii) a copolymer of about 80 mole percent ethylene and about 20 mole percent 1-butene.

15 53. A polymer blend according to Claim 52, comprising one part by weight of component (i) and about 0.25 to about 4 parts by weight of component (ii).

20 54. A polymer blend according to Claim 50 in the form of a sealing member.

25 55. A sealing member according to Claim 54 in the form of a diaphragm, an O-ring, or a gasket.

56. A method of sealing a chamber with a sealing member, comprising the step of sealing said chamber with a sealing member according to Claim 41.

1/1




FIG. 1




FIG. 2